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Heat shock protein 90 (Hsp90) represents an important chemotherapeutic target in the treatment
of various ailments including cancer and neurodegenerative diseases. The protein is responsible
for controlling and regulating the growth of nearly 200 client proteins known to overexpress
in tumour or cancer cells. Targeting Hsp90 and inhibiting its chaperone machinery function
results in proteasome degradation of the client protein and hence treatment of the disease. In
this thesis, different computational docking protocols, the role of water and conformational
fluctuations in drug design for the discovery and identification of new Hsp90 inhibitors are
reported. In particular, the sensitivity of different docking protocols to crystal structure with
and without water, relaxed complex scheme (RCS) or ensemble-based structures holo and apo
structures with and without water, the effects of including a different amount of water in the
protein active site on the thermodynamics of ligand binding to protein structures are reported.
There is sensitivity of results to different docking protocols, RCS lowers the binding energy in
comparison to crystal structure, holo ensemble with strong ligand bound improves the dock-
ing results. Since biological activities of small molecules highly depends on the conformation,
molecular structure, charge distribution and non-trivial response to solvents. The thesis fur-
ther explored the role of different solvents viz polar protic, polar aprotic, and non-polar on
the conformation of curcumin as a model drug/natural product. Well-tempered metadynamics
(WT-MetaD), an enhanced sampling method employing OPLS-AA force field in an isobaric-
isothermal (NPT) ensemble was used to investigate the related solvent effects. The orientation
and conformational of curcumin was solvent dependent, the free energy for curcumin in sol-
vents and vacuum portrayed a different behaviour. Curcumin exists in different configuration
and conformations in different solvents. The trans-conformation was more stable in polar apro-
tic solvents capable of solubilizing curcumin whereas the cis-conformation was more stable in
polar protic solvents i.e water where it has marginal solubility. Finally, the thesis reports on the
influence of solvents on kinetics and residence time of drug unbinding in host-guest complexes.
The effect of polar aprotic and polar protic solvents on kinetics and residence time of drug un-
binding from a nanoparticle was investigated using chitosan-toussantine-A as a model system.
WT-MetaD was used to study the kinetics and residence time. Results show that the kinetics
and residence time of drug unbinding was affected by solvents. Slow unbinding kinetics of
koff = 0.045 µs−1 was observed for the system formulated with water, a polar protic solvent,
while fast unbinding kinetics with koff = 1000 µs−1 was observed in system formulated with
DMSO solvent. Furthermore, the interaction of chitosan-toussantine-A complex in water was
observed to be stable than in DMSO. The approaches used in this thesis pave the ways and can
further be extended to investigate more problems in drug design ranging from protein-ligand
interaction, solution conformation of small molecules and host-guest kinetics. Since the new
reported small molecules as Hsp90 inhibitors are approved for other indication, the inhibitors
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1.1 Background of the problem
1.1.1 Brief introduction of heat shock proteins (HSPs) and their role in cancer treatment
It is well acknowledged that when cells are exposed to environmental or physiological stress,
such as ultraviolet light, mechanical stress, anoxia, hyperthermia and toxin. One of the de-
fensive response is to instruct the synthesis of a small group of a protein called heat shock
proteins. Heat shock proteins (HSPs) are families of molecular chaperone mostly expressed
and conserved in all cellular organism and performs several roles in eukaryotic cells. The pri-
mary role of HSPs is to maintain and correct the function of protein machinery by maintaining
the structure and folding of the client proteins when cells are exposed to homeostatic environ-
ment (Chatterjee & Burns, 2017; Li et al., 2009; Swuec & Barlow, 2012; Proia et al., 2015).
The expression of the HSP to different stress factors is known as Heat Shock Response (HSR)
regulated at the transcription level by heat shock factors (HSFs) which is the highest transcrip-
tion regulator of HSPs (Chatterjee & Burns, 2017). HSFs are highly conserved N-terminal
binding domain as well as C-terminal transactivation domain and are grouped as HSF1,2,3,4
and HSFY (Chatterjee & Burns, 2017). Of these HSFs, HSF1 mostly regulates HSR as well
as HSP gene expression via genes known as heat shock elements (HSE) as shown in Fig. 1.
HSF1 works by modulating the expression of HSP. During stress condition, HSF1 is triggered
in the cytoplasm by HSP70/90 which binds to HSF1 to block its transcription action. When
responding to external stress, HSP separate from to activate HSF1 which binds to HSE by ac-
tivating HSP genes for promoting cellular protection. Depending on the size and molecular
weight HSPs are classified as Hsps 40, 60, 70, 90 and 100. Heat shock protein 90 (Hsp90) is
of the most interest and has attracted attention due to its multiple functions (Eachkoti et al.,
2014). It is mostly involved in folding and stabilization of numerous protein including those
which contribute to the development of cancer (Sauvage et al., 2017). The focus of this the-
sis is on the Hsp90 as a cancer chemotherapeutic target and is discussed in details in the next
subsection.
1.1.2 Structure and function of Hsp90 as cancer chemotherapeutic target
Heat shock protein 90 (Hsp90) is a 90 kDa molecular chaperone highly abundant in stress re-
sponses (Proia et al., 2015), with the primary role of controlling cell survival (cell growth and
development) (Swuec & Barlow, 2012; Gupta et al., 2015), stabilization and maintaining the
active conformations of steroid hormone receptors (Swuec & Barlow, 2012; Jiang et al., 2016;
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Figure 1: Regulation of HSR and HSP via HSE binding. Adapted from Chatterjee and Burns, (2017).
Yun et al., 2011). It also controls the functions of many signalling proteins such as those in-
volved in pathways of cell proliferation, angiogenesis, cell cycle progression, metastasis and
invasion (Li et al., 2009). Over 200 known client proteins expressed in tumour cells depend on
Hsp90 for their functions, growth, folding and maturity (Swuec & Barlow, 2012; Proia et al.,
2015; Li et al., 2009; Eachkoti et al., 2014; Shi et al., 2012; Sha & Cao, 2015). Such client
proteins include; kinases such as CDK, BRAF, AKT, BCR-ABL, CRAF and AGFR. Others
are transcription factors such as oestrogen and androgen receptors (AR), p53 and HIF-1 (Proia
et al., 2015; Li et al., 2009; Eachkoti et al., 2014; Shi et al., 2012). Thus, Hsp90 has been
considered as a potential chemotherapeutic target for the treatment of cancer and other diseases
such as alzheimer, parkinson and cardiovascular diseases (Swuec & Barlow, 2012). Inhibition
of Hsp90 functions results in the simultaneous depletion of several client proteins (Eachkoti
et al., 2014) as well as degradation of oncogenic protein, by stopping multiple signalling trans-
duction pathways of different cancer cells and hence bringing broader anticancer effects (Jiang
et al., 2016; Shi et al., 2012).
The structure of Hsp90 (Fig. 2) is composed of three functional domains namely; N-terminal
adenosine triphosphate/adenosine diphosphate (ATP/ADP) binding domain, middle domain
concerned with client protein binding, and a C-terminal dimerization domain (Proia et al.,
2015; Jiang et al., 2016; Shi et al., 2012; Sauvage et al., 2017). The function of the Hsp90
chaperone depends on the domains conformation changes driven by nucleotide binding, hy-
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drolysis and exchange of ATP to ADP in the N-terminal domain as well as on the interaction of
the client proteins (Sauvage et al., 2017). Several compounds are designed to bind at the ATP-
binding site to inhibit the function of Hsp90 (Jiang et al., 2016). In addition, the C-terminal
domain has shown a second ATP binding site which needs further exploration (Sauvage et al.,
2017).
(a) (b)
Figure 2: (a) The structure of Hsp90 functioning machinery. (b) The changes of the binding client
protein affects the conformation of Hsp90 resulting to N-terminal ATP/ADP binding site to
open and close. Adapted from Sauvage et al. (2017).
An accumulation of evidence showing Hsp90 as a potential cancer target already exists (Barker
et al., 2010; Krukenberg et al., 2011; Meyer et al., 2003; Cavenagh et al., 2017). Pharmacolog-
ical inhibition of Hsp90 results in destabilization and proteasome destruction of client proteins
(Sha & Cao, 2015; Gewirth, 2016). Thus, drug candidates are designed to target Hsp90 for the
treatment of various cancers and neurodegenerative diseases.
1.1.3 Inhibitors of Hsp90
Several Hsp90 inhibitors (Fig. 3) have been reported over the past years (Roe et al., 1999;
Wang et al., 2006; Ge et al., 2006; Tian et al., 2004). Currently, about 20 Hsp90 inhibitors are
in clinical trials (Bhat et al., 2014). Two structurally unrelated natural products geldanamycin
(1), a benzoquinone ansamycin antibiotic and radicicol (2) were the first reported Hsp90 in-
hibitors (Roe et al., 1999). Both compounds showed strong anticancer activities by inducing
protein degradation through proteasome but did not progress into clinical trials (Roe et al.,
1999). Poor in vivo activities, liver toxicity, poor aqueous solubility and difficulties in formu-
lation/production were the clinical limitations for these class of compounds to enter into phase
I clinical trial (Soga et al., 2013). Two geldanamycin derivatives; 17-allylamino-demethoxy
geldanamycin (17-AAG, tanespimycin (3)) and 17-dimethylamino-geldanamycin (17-DMAG,
alvespimycin (4)) were synthesized and entered into phase I clinical trials (Ge et al., 2006;
Tian et al., 2004; Hertlein et al., 2010). In clinical trials, 17-AAG (3) showed strong tumour
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selectivity and it has been tested as monotherapy or in combination with other agents. Clinical
uses of 17-AAG (3) were limited due to poor solubility and difficulty in formulation (Ge et al.,
2006; Tian et al., 2004; Hertlein et al., 2010). 17-DMAG (4) was synthesized to overcome sol-
ubility problems of 17-AAG (3). Although 17-DMAG (4) showed strong Hsp90 inhibition and
good aqueous solubility, further progress in clinical trials was hindered by its toxicities (Chio-
sis, 2006). Classes of compounds with purine scaffolds were then designed and synthesized as
Hsp90 inhibitors. Some of these compounds are in preclinical and clinical trials. For instance,
BIIB021 (5) is in phase I and II clinical trials for patient with metastatic breast cancer. Other
purine compounds such as SNX-5422 (6) and SN-38 (7) were designed and entered into phase
I clinical trials. However, they were stopped due to ocular toxicity as well as irreversible retinal
damage (Peterson, 2012). None purine compounds, for example, docetaxel (8) and gambogic
acid (9) have shown promising activities. Despite the strong activities shown by these classes
of compounds, their clinical uses have been hampered by many factors including toxicities and

















































































Figure 3: Chemical structures of potential Hsp90 inhibitors clinically limited due to their poor pharma-
cokinetic.
The major clinical limitation of many drugs is related to their; low efficacy, pharmacologi-
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cal toxicity and non-appropriate pharmacokinetic properties of the drug candidate(s) (Puccetti
et al., 2005). Such properties were studied during the development phases, while, instead they
should have been investigated prior to the development phase. This results in the discovery of
related adverse effects and toxicity at a very late stage, a reason for many drugs failure and
discontinuity from clinical trials. Until now, there are no approved Hsp90 inhibitors.
Today, advances in computational (in silico) methods have provided a means of studying bio-
logical activities, pharmacological and pharmacokinetic properties of potential lead compounds
before they enter into pre-clinical and clinical trials (Ntie-Kang et al., 2013). Furthermore,
computational methods are gaining significant attention in drug repurposing (Sohraby et al.,
2019). In particular, molecular docking is a well established and known method in structure
based drug design, discovery and development. It predicts the binding free energy of the 3D
structure i.e the protein (receptor) and the drug (ligand or small molecule) (De Vivo et al.,
2016). Several protocols and tools for performing molecular docking in structure based drug
design have been developed. Some protocols for example, consider docking small molecules
to the static crystal structure of the protein without water (Kavitha & Velraj, 2017; Qin et al.,
2015). It has been shown however that, water plays an important role during protein-ligand
interaction (Rarey et al., 1999; Santos et al., 2009; Cui et al., 2018; Huang et al., 2015; Bis-
santz et al., 2010). Other docking protocols have considered water molecules during molecular
docking on the crystal protein structure (Roberts & Mancera, 2008; Thilagavathi & Mancera,
2010; Kumar & Zhang, 2013). Such protocols have shown an increase of docking accuracy
when water is included in the binding pocket. Other protocols have showed that, inclusion of
water depends on the nature of the ligand, protein system, scoring function as well as the dock-
ing methods used (Kumar & Zhang, 2013).
Although incorporation of water into the crystal structure of the protein during molecular dock-
ing has shown success and improves the binding energy of some ligands, the approach is com-
plicated by global flexibility of the protein (Roberts & Mancera, 2008). To address this chal-
lenge, the relaxed complex scheme (RCS) (Lin et al., 2002) was developed. In this protocol,
a molecular dynamics simulation of the protein is performed and after equilibration, receptor
configuration are generated and selected for docking. The selected receptor ensembles (snap-
shots) account for the structure flexibility of the protein for ligand binding (Lin et al., 2002;
Roberts & Mancera, 2008). Since the invention of RCS protocol (Lin et al., 2002; Schames
et al., 2004) several reports by (Barakat & Tuszynski, 2011; Barakat et al., 2010; Chan et al.,
2013) to mention a few, have shown success of using RCS in drug design and discovery. How-
ever, the role of water has been neglected in most reports (Barakat & Tuszynski, 2011; Barakat
et al., 2010; Chan et al., 2013; Cheng et al., 2008). Reports have shown that water has effects
on the binding energy of ligands when docked to different receptor ensembles (Santos et al.,
2009). Besides the role of water, other factors that can affect the docking predication is when
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one docks ligands to apo or holo conformation (Cheng et al., 2008; Barakat et al., 2010; Michel
& Cuchillo, 2012).
In this thesis, different docking protocols for repurposing FDA-approved drugs as Hsp90 in-
hibitors are investigated. In particular, the effects of inclusion of water in the protein active site
of both holo and apo protein structures from the MD simulation are investigated. The finding
shows a strong sensitivity to the details of the docking protocol: the use of crystal structure
versus an ensemble structures from a simulation, docking with and without water, and finally
docking into apo or holo structures.
1.1.4 The role of solvents on host-guest thermodynamics, kinetics and residence time
It is well contented that in drug design, solvents play an important role as they are used in drug
formulation, determining the rates of chemical reaction and folding kinetics of molecules (Fu
et al., 2014; Papadakis & Deligkiozi, 2019; Levy et al., 2001; da Silva et al., 2018; Sheehan
& Sharratt, 1998; Slakman & West, 2019). In many chemical reactions, solvents are known
to influence the rate of chemical reaction by controlling the diffusion and rates of the reac-
tants. Difference in solvent dielectric constant, polarizability and polarity are among the fac-
tors known to affect the rate of reaction in many biological systems. Exploration of solvent
effects on supramolecular interaction (Fu et al., 2014; Papadakis & Deligkiozi, 2019), folding
kinetics of biological molecules (Levy et al., 2001) chemical reaction (da Silva et al., 2018;
Sheehan & Sharratt, 1998; Slakman & West, 2019) not only has gained much attention in the
recent decade but also it has become an active area of research among chemists and chemical
physicists. For example, the effect of solvents on thermodynamic stability of supramolecu-
lar complexes has been investigated before and found that different polarity in solvents results
into different thermodynamic stability in supramolecular recognition (Papadakis & Deligkiozi,
2019). In their work Kang et al., investigated the supramolecular binding of host-guest based
on 1-adamantanecarboxylic acid and found that the interaction was entropically favoured, with
less polar solvents showing a reverse processes on supramolecular recognition/binding (Kang
& Rebek Jr, 1996). Neutral and ionic species such as potassium ions are also involved in
supramolecular interactions and solvent effects were also observed for host-guest interactions
involving such ions and largely depend on the guest molecule in a given host molecule (Pa-
padakis & Deligkiozi, 2019). As an example, using the linear free energy approach, the host-
guest complexation of cyclophane, a hydrophobic molecule and crown ether-18-crown-6 in-
volving potassium ion has been carried out. The association constant of cyclophane was ob-
served to be higher 5-folds in water than in carbon disulfide for a pyrene-cyclophane complex
(Smithrud & Diederich, 1990; Izatt et al., 1995). The aforementioned examples, provide an
underlying basis on the related solvent effects on kinetics and thermodynamic stability in host-
guest interactions. This thesis investigated the solvent related effects on the thermodynamics
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and kinetics of host-guest based on chitosan-toussantine-A complex using metadynamics and
thermodynamics integration approaches. A detailed literature review on solution conformation
of natural products as well as chitosan nanoparticle based drug delivery is given in Chapter 2.
1.2 Statement of the problem
Molecular chaperones are important chemotherapeutic targets in treatments of various diseases.
HSPs are chaperones which in recent years have proved to be important targets in the treatment
of cancer (Barker et al., 2010; Krukenberg et al., 2011; Meyer et al., 2003; Cavenagh et al.,
2017). Of all the HSPs molecular chaperones, Hsp90 has become an important target in cancer
treatment. Several efforts to identify potential Hsp90 inhibitors have been attempted. Despite
of such efforts, until now there is no any approved Hsp90 inhibitors for cancer treatment. Sev-
eral approaches, experimental and computational have been employed in investigating Hsp90
inhibitors. Although, experimental methods have provided some useful insights into the prob-
lems, further exploration has been limited due to higher degree of similarities of the Hsp90 iso-
forms (Sha & Cao, 2015). The use of computer simulations can aid experimental approaches
in exploration and identification of specific Hsp90 isoform inhibitors. In light of this, several
computational protocols such as molecular docking have been employed at large, however,
have presented a gap on how such protocols are applied to solve specific problem in drug de-
sign. Such protocols have considered thermodynamic information based on static structure of
the protein. In addition, the role of water and conformational fluctuation in the Hsp90 has
been given less attention and remain unaddressable issue in previous works, such issues are
addressed in this thesis. Furthermore, solvent effect on conformation and kinetics of small
molecule with their host molecule has been investigated considering thermodynamic data. This
gave an opportunity for this study to explore and investigate different docking protocols, the
role of water and conformation fluctuation in drug design. The thesis further explored solvent
related effects on drugs/natural products conformation and host-guest kinetics and residence
time.
1.3 Rationale of the study
The process of drug design, discovery and development is lengthy, costly and a challenging
processes. Very recently, the advert of computer hardware and development of algorithms has
helped scientists to design and develop drugs in a short time and reduced the related costs. Also,
many drugs discovered using traditional drug design approaches are withdrawing from clinical
uses due to undesirable pharmacokinetics properties. Such properties were studied during the
development phase, instead they should be investigated prior to clinical testing or development.
Computer aided drug design approaches have provided a better way to study such properties
prior to clinical testing. Owing to the role played by computers in aiding the process of drug
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design, this thesis employed various computational methods to study the role of solvents and
conformational fluctuations of macromolecules towards drug design.
1.4 Objectives
1.4.1 General objective
The general objective of this thesis is to understand the role played by both solvents and con-
formational fluctuation of macromolecules and small molecules, which play an important role
in determining the biological activities of small molecule under investigation.
1.4.2 Specific objectives
The specific objectives of the present thesis are to:
(i) Compare different docking protocols used in drug design using Hsp90 as a molecular
target in cancer treatment.
(ii) Evaluate the solution conformation of drugs/ natural products using curcumin as a model
molecule.
(iii) Assess the solvent effects on drug-nanoparticle kinetics and residence time using chitosan-
toussantine-A complex as a model system.
1.5 Research questions
(i) What are the sensitivity of different docking protocols used in drug design for the discov-
ery of Hsp90 inhibitors?
(ii) How solvent affects the conformation and orientations of curcumin a model natural prod-
uct?
(iii) How solvent affects the kinetics and residence time of toussantine-A bound to chitosan
nanoparticle?
1.6 Significance of the study
Drug design and discovery is a challenging, costly and lengthy process. The development
of computer hardware and algorithms have helped scientists to a great extend to shorten and
reduce the related costs. Although, there is an advancement in drug design using computer
simulations, several aspects need to be given attention. For example, the effect of solvents and
conformation of macromolecules are important factors to be considered. Unfortunately, much
efforts have been directed only in understanding the thermodynamics of drug binding, with
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little efforts directed on understanding the role of solvents and conformational fluctuations.
In addition, drug kinetics and residence time are important factors which have gained less
priority. This work has contributed by studying different docking protocols used in drug design,
furthermore, the influence of solvents on drug conformation, kinetics and residence time are
reported in this thesis. These results are important in the drug design and discovery process.
The methods and approaches used in this thesis can further be extended to identify and design
other drugs for different indications.
1.7 Delineation of the study
Due to the growing importance of in silico drug design which has helped scientists to study
molecules at atomistic level. The work reported in this thesis was performed employing dif-
ferent in silico approaches viz molecular docking, molecular dynamics and enhanced sampling





In structure based drug design, macromolecules such as protein, DNA and RNA are targets for
bioactive agents in the treatment of many diseases. The association of macromolecules and
biologically active agents (ligands) has a great role in regulating their functions. Molecular
docking is a powerful tool used to find the most favourable binding mode of the ligand when
binds to the macromolecule to form a complex. Due to the importance of molecular docking in
drug design, over the past decades, several docking programs and algorithms to perform molec-
ular docking have been developed, tested and used in drug design to predict and discriminate
between good and bad binders (Ntie-Kang et al., 2013; Sohraby et al., 2019). Such docking
programs includes: FLExX (Kramer et al., 1999; Schneider et al., 2013), AUTODOCK/VINA
(Trott & Olson, 2010; Morris et al., 1998) MS-DOCK (Sauton et al., 2008), GOLD (Verdonk
et al., 2003) and SURFLEX (Jain, 2003) to mention a few. For a detailed and comprehesive re-
view on docking algorithms a reader is refereed to Dias et al. (2008). These docking programs
are based on different scoring functions and specific search algorithms such as incremental al-
gorithm, genetic algorithm and Monte Carlo. The former can be grouped into three categories:
empirical based, knowledge based and force-field based scoring function (Dias et al., 2008).
The scoring functions implemented in many docking programs are able to estimate the bind-
ing free energy (∆G) or binding constant (Ki). The former ∆G is obtained from the Gibbs-
Helmholtz as:
∆G = ∆H−T ∆S (2.1)
where ∆G is the binding free energy, ∆H is the enthlapy, T is the temperature in Kelvin and ∆S
is the entropy. The binding constant (Ki) is related to ∆G as:
∆G =−RT ln Ki (2.2)
In this study, FlexX part of leadIT was used to introduce the basic concepts of molecular dock-
ing. As discussed in the material and methods section, FlexX employs an incremental con-
struction algorithm to bring a ligand into the active site. The ligand is usually decomposed into
several fragments, then ligand reconstruction is guided by the protein active site using various
placement strategies (Kramer et al., 1999). The binding free energy is calculated and assessed
by using the HYDE (HYdrogen bond and DEhydration energy in protein-ligand complex) scor-







During HYDE calculations, the hydrophobic and hydrophilic dehydration contributions are cal-
culated separately (Schneider et al., 2013) as follows:
∆Gi, hydrophobicdehydration =−2.3RT · plogPi · (acciunbound− accibound) (2.4)
∆Gi,hydrophilicdehydration =−2.3RT · plogPi · f ibur · f iwater ∑
H-bonds functions j
w j.P jdehydration (2.5)
f iwater is calculated by using equation:
f iwater = ∑




where; p jdehyd is the probability of dehydration of each hydrogen bond function j (H-bond donor
or acceptor); wi is the weight for multiple H-bonds formed by hydrophilic atoms; f ibur is the
scaling factor for buriedness of a hydrophilic groups in the unbound state and f iwater is the cor-
rection factor for local arrangement of water in proximity to H-bond function (Schneider et al.,
2013). For docking experiments involving water, the hydration sites of the protein in the ac-
tive site is determined using the particle concept algorithm (Rarey et al., 1999) implemented in
FlexX.
Although molecular docking is faster in calculating the binding free energy, it has limitation
related to conformational fluctuation of the macromolecules. Many docking algorithms do not
allow the flexibility of the protein. Some algorithms allow only for the side chain flexibility
during molecular docking. This limitation has necessitated the rise of new approaches to over-
come such a problem. One of such approach is the relaxed complex scheme (RCS) (Amaro
et al., 2008b; Schames et al., 2004; Durrant & McCammon, 2011). In RCS, one needs to run
MD simulation and extract many ensemble structures which are then subjected to molecular
docking programs. Molecular dynamics simulation is performed to provide dynamic and fluc-
tuations of the complexes. Although RCS approach provides flexibility of the protein structure,
it is limited by the docking algorithms which require a rigid protein structure (Durrant & Mc-
Cammon, 2011). In the next section molecular dynamics simulation as a tool in studying not




Molecular dynamics (MD) simulations are computational simulation methods which enable the
movement of molecules or atoms at a nano scale. In a molecular dynamics simulation particles
are allowed to interact with each other at a given time, resulting in producing a trajectory which
contains information about the dynamical behaviour of the studied system. This section of the
thesis starts by discussing the basic ingredients of molecular dynamics. In order to perform
a molecular dynamics simulation of a system of interest, one needs to specify the initial con-
ditions i.e velocities and positions of every particle in a system at time zero and interaction
potential for deriving the forces among all the particles. Then, the system evolved in time is
solved by a set of classical equations of motion for all particles in the system.
In classical mechanics, the force is calculated as the derivative of the interacting potential,
V(R), and the force acting on each particle in the system is determined using the Equation 2.7.




Equation 2.7 provides a set of 3N coupled second order differential Equations that can be
propagated forward and backward in time. In Equation 2.7, Fi represents a vectorial sum of
all forces acting on ith particle of the system. The forces are derived from a potential energy
function V(rN) that describes how particles in a given system interact to each other. Equation
2.7 is solved by integration using a small time steps in an order of magnitude ranging between
1 to 10 fs. This implies that at every time step of the simulation, both positions and velocities of
every single atom are calculated. The initial positions and velocity need to be known, usually
specified in an input datafile, and the forces are calculated through the potential energy. The
initial coordinates at t = 0 is obtained from experimental data while the velocities are not known
and they need to be assigned. Assigning of velocity can be done using a Maxwell-Boltzmann
distribution at a given temperature, usually at 300 K for many biological systems.
2.2.1 Energy minimization
Since the starting configurations are obtained from experimental data, usually in their crystal-
lographic structures they are far from equilibrium. Thus, an energy minimization is needed to
be done before performing MD simulation. Energy minimization is done to reduce the exces-
sively large interaction forces within atoms, and therefore, bring the system at a relaxed state.
Algorithms such as steepest descent (SD), conjugate gradient (CG) and Newton’s methods are
used to do energy minimization.
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2.2.2 Force fields
Due to the current limitation of computational resources, it is not possible to accurately calcu-
late the potential energy of macromolecules by using quantum chemistry electronic approaches.
Thus, force fields which are simple classical functions with a number of parameters from either
experimental data or quantum chemistry calculation are used. A force field is, therefore, a set
of parameters containing specific function which describes the interaction of atoms. Generally,
a force field contains functional terms such as Lennard-Jones, coulomb, harmonic vibration
and model parameters which describe the function terms. Several families of force field are
available for molecular simulations, for example, AMBER (Lindorff-Larsen et al., 2010; Wang
et al., 2004), CHARMM27 (MacKerell Jr et al., 2000), GROMOS (Oostenbrink et al., 2004)
and OPLS (Jorgensen & Tirado-Rives, 1988; Jorgensen et al., 1996). Since these force fields
are used for different systems, one has to choose the force field depending on the system to
be simulated. In this thesis AMBER03 and OPLS-AA force fields are used and described in
details, in particular, the OPLS (Optimized Potential for Liquid Systems) force field which has
a potential function form described in Equation 2.8.
V (rN) = ∑
bonds


























V Coulombi j (ri j)+V
LJ
i j (ri j)
] (2.8)
In Equation 2.8 each term is an approximation for different interaction energy, and the first
three terms represent covalently bonded terms linked by bonds (l), angles (θ ) and torsions (φ ),
while the last term represents non-bonded term for long-range electrostatic and van der Waals
energies (Lennard-Jones 6-12 potential) (Jorgensen & Tirado-Rives, 1988; Jorgensen et al.,
1996).
2.2.3 Integrating the equation of motion
Once the forces for each atom are obtained from the force field, both velocity and position at
every particle at t = t0 +∆t can now be computed by integrating Equation 2.7. In general, the
time step ∆t, is a small number with the order of (1 f s = 10−15s), the use of longer time steps
usually affect the simulation and conservation of energy.
Several algorithms such as Verlet (Verlet, 1967), velocity Verlet (Swope et al., 1982), Leap frog
(Van Gunsteren & Berendsen, 1988) are available and used to integrate the Newtons equation
of motion. Here, the Verlet algorithm which is often used to integrate the equation of motion
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is described (Verlet, 1967). This algorithm is derived by the Taylor expansion of coordinate of










~ri(t +∆t) = 2~ri(t)−~ri(t−∆t)+~ai(t)∆t2 +O(∆t4)
~ri(t +∆t)≈ 2~ri(t)−~ri(t−∆t)+~ai(t)∆t2. (2.10)
Equation 2.10 can be implemented in classical molecular dynamics to propagate the positions
of each atom at a time. In this Equation 2.10 the estimation of new position contains an error
in the order of ∆t4. However, this equation does not explicitly include the velocity terms. The





2.3 Metadynamics as an enhanced sampling method
Despite the fact that MD simulation is widely used in many aspects, it suffers from sampling
problem and time scale, as it does not allow escape from local free energy minimum and re-
quires long time for the system to reach ergodicity (Laio & Parrinello, 2002; Barducci et al.,
2008). To overcome such limitations, several algorithms in the name of enhanced sampling
methods such as metadynamics (Laio & Parrinello, 2002; Barducci et al., 2008), umbrella
sampling (Kästner, 2011) and conformational flooding (Grubmüller, 1995) to name a few have
been introduced.
2.3.1 Theory of metadynamics
Metadynamics is one of the enhanced sampling methods used to sample rare events (Laio &
Parrinello, 2002). In metadynamics, the added bias potential discourages the system from revis-
iting already visited phase space allowing one to surmount energy barriers. Figure 4 provides
a picture on how metadynamics work. Consider a system of N-particles interacting with the
potential V (r) in a canonical ensemble with a temperature T . In a given system, if a dynamics
stucks at one local energy minimum with V (r), the probability to escape to other local mini-
mum is low. In metadynamics, a history-dependent bias potential, V (r), constructed along the
selected reaction coordinate~s(q), called collective variables (CVs) is added to the Hamiltonian
of the system as follows:
14
H = T +U +V (r) (2.12)
where 2.12, T is the total kinetic energy, U is the potential energy which describe the system
and V (r) is the bias potential. This potential is built as a sum of Gaussian kernels (height (W )
and width (δi)) deposited along the trajectory in the CVs space, and can be written as:












where t is the deposition time and τ is the time interval where Gaussian potential with height is
added on the position si (q(k τ)) of the biased molecules.
Figure 4, describes how metadynamics work for a simple 1D potential with two minima, i.e
one for reactant and one for product. In (A) the reaction is at local minimum, then the bias
potential is added during the simulation as shown in (B) to discourage the system to revisit
already visited phase space, at this point the bias potential is sampling around the minimum.
In (C) the added bias potential is large enough forcing the system (in blue) to move to another
global energy minimum on the right side. In (D) the added bias potential becomes large than
the free energy barrier and the system can easily move from one minimum to another.
Although metadynamics has several benefits, its implementation is faced up by two disadvan-
tages. Firstly, the choice of collective variable (CVs) is nontrivial and a complicated process,
as there is no systematic way of selecting appropriate CVs. The Gaussian sigma are chosen
from a short standard MD simulation which can provide an overview of the system. The other
disadvantage is the difficult in bias potential to converge the underlying potential energy due to
the constant height of Gaussian hills.
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Figure 4: An illustration of how metadynamics work. The blue point represents the position of the sys-
tem in an arbitrary free energy along the reaction coordinate δ (CVs). Adapted from Jambrina
and Aldegunde (2016).
In order to control errors and convergence during metadynamics simulation, well-tempered
metadynamics (WT-MetaD), which is a variant of metadynamics was introduced (Barducci
et al., 2008). In WT-MetaD the Gaussian height (W ) decreases with simulation time as shown
in Equation. 2.14.






where, W0 is the initial Gaussian height, kB is the Boltzmann constant, ∆T is the input parameter
with dimension of temperature that control how the W reduces as the well is filled. To obtain




V (~s, t→ ∞) (2.15)
where, ∆T is the input parameter with dimension of temperature, T is the temperature of the
system. In well-tempered metadynamics the bias factor γ is defined as the ratio between the





2.3.2 Reweighting free energy
During metadynamics simulation, the free energy is calculated using the biased CVs, the free
energies of the unbised CVs can be calculated by reweighting approaches. The probability
distribution of the biased CVs from the trajectory is obtained as in Equation 2.17. The quan-










Very recently, a simple reweighting algorithm to recover distribution of unbiased CVs was
developed by Tiwary and Perrinello (Tiwary & Parrinello, 2014). Based on this algorithm, by
using the internal potential U(−→r , t) and the bias potential V (−→s , t), the probability distribution
P(−→r , t) can be written as:
P(−→r , t) = exp(−β (U(
−→r , t)+V (s(−→r , t)))∫
d−→r exp(−β (U(−→r , t)+V (s(−→r , t))) (2.18)
Equation 2.18 can be rewritten in the following form:
P(−→r , t) = exp(−β (V (s(−→r , t)− c(t)) ·Po(−→r ) (2.19)
where Po(−→r ) is the probability distribution which is not biased, c(t) is time dependent function














+V (−→s , t) (2.20)













γV (−→s , t)/kBT
)]
(2.21)
In Equation 2.21, detσ is the determinant of the collective variable space and ∆t is the time
interval between Gaussian depositions.
2.4 Binding free energy in drug design and discovery
It has been mentioned that accurate predication of the affinity of drug to its target receptor
(protein or nanocarrier), is one of the holy grails in computational drug design (Aldeghi et al.,
2016; Ytreberg et al., 2006). Free energy calculations (∆F) are of particular interest, and have
a variety of applications in drug design (Aldeghi et al., 2016; Ytreberg et al., 2006), such as
protein-ligand interaction (Aldeghi et al., 2016; Ytreberg et al., 2006; Peräkylä & Nordman,
2001) and solubility of small molecules. Free energy calculation has raised interest to both
experimental and computational/theoretical communities (Ytreberg et al., 2006; Ytreberg et al.,
2006). Due to its importance in the field of drug design, several methods have been developed.
Exisiting free energy methods are classified as equilibrium and nonequilibrium. Equilibrium
free energy are those which requires or relies on fully sampled equilibrium simulation done
in each step of the free energy calculation. Such methods includes free energy pertubation
(FEP) (Rao et al., 1987), MM-PB(GB)SA (Kollman et al., 2000), thermodynamics integration
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(Kirkwood, 1935), weighted histogram analysis (Kumar et al., 1992) and Bennett analysis
(Shirts & Pande, 2005). In equilibrium free energy, one needs to attain the equilibration at
each stage to avoid obtaining biased results. On the other hand, nonequilibrium free energies
based on Jarzynski’s equality have recently been used in many molecular systems, however
they suffer from bias. This work describes equilibrium free energy which is central of this
work. Readers interested in nonequilibrium free energy are refereed to (Jarzynski, 1997).
2.4.1 Thermodynamic integration
Thermodynamic integration (TI) is one of the mostly reported accurate alchemical method used
to calculate/compare the free energy of two given states A and B (see Fig. 5). The two given
states have their potential energies UA and UB with different dependence on coordinates. In
TI, the free energy is calculated using a thermodynamic path from state A to B by integrating
over the ensemble average along the path. As shown in Fig. 5, the potential energy UA and UB
is calculated as an ensemble average over the sampled phase space from molecular dynamics
(MD) or Monte Carlo (MC) simulation. A new potential function is defined as:
U(λ ) =UA +λ (UB−UA) (2.22)
Here, λ , is a coupling paramenter with the value ranging from 0 to 1. The potential energy as a
function of λ varies from the energy of system A for λ = 0 and system B for λ = 1. Taking an
example for canonical ensemble, the partition function of the system can be writen as follows:







Us(λ ) is the potential energy of state S in the ensemble function U(λ ). The corresponding free
energy of the system can be defined as follows,
∆G(N,V,T,λ ) =−kBT lnQ(N,V,T,λ ) (2.24)
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Figure 5: Thermodynamic cycle. Figure adapted from alchemical website at www.
alchemistry.org/wiki/Thermodynamic cycle.
Taking the derivative of G with respect to λ , one can get an ensemble average of the derivative













































Thus, the free energy can be computed from the integral of the ensemble average derivatives
of potential energy using a compling parameter, λ . Generally, TI is most accurate method of
estimating the binding free energy as it needs extensive sampling of both complex and ligand
in solution and the unphysical intermediate states.
2.4.2 Molecular Mechanics Poisson-Boltzmann (Generalized Born) Surface Area (MM-
PB(GB)SA)
In structure-based drug design (SBDD), one of the important goal is to identify new small
molecules (ligands) which can bind to their macromolecules receptors. The binding of a ligand
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to their receptors is described in the following chemical reaction:
R+L→ R : L (2.29)
where, R denotes receptor usually protein, DNA or any macromolecule, L denotes a ligand. The
strength of the ligand binding to macromolecules is determined by calculating the binding free
energy, ∆Gbind. Normally, this free energy is determined using experimental approaches, which
again suffer from the limitation of high cost and time consuming. Thus, several computational
methods have been developed with the aim of reducing both cost and time while achieving the
goal of drug design.
MM-PB(GB)SA is the most popular method used to estimate the binding free energy, ∆Gbind of
ligands to their macromolecules in drug design. Although, MM-PBSA depends on molecular
dynamics simulation of the complex, it does not demand high computational cost unlike the
alchemical pertubation (AP) approaches. However, the accuracy of MM-PBSA lies between
the scoring and AP approaches. Because of less computational demand and the accuracy, today,
MM-PBSA is used in many systems to estimate the binding affinity of ligands with different
degree of success. In MM-PBSA, the ∆Gbind from Equation 2.29 is obtained by estimating the














This method in Equation 2.30 was first reported by (Kollman et al., 2000) and it has signifi-
cantly gained attention in many application ranging from protein-ligand interaction (Aldeghi
et al., 2016; Ytreberg et al., 2006), protein-protein interaction (Chen et al., 2016) as well as
conformational stability (Brice & Dominy, 2011). The free energy of each state RL, R and L
in equation 2.30 is estimated as the sum of the following components (Kollman et al., 2000).
G = Ebonded +Eele +EvdW +Gpolar +Gnon-polar−T S (2.31)
(i) Molecular mechanics (MM) energy terms
The first three terms in Equation 2.31 are molecular mechanics (MM) energy terms from
bonded, electrostatic and van der Waals interactions. The next two terms, that is, polar and
non-polar contribute to solvation free energies. The former is obtained by solving the Poisson-
Boltzman (PB) or Generalized Born (GB) equation giving the term MM-PBSA or MM-GBSA.
The non-polar contributions is estimated by linearly relating to the solvate accessible surface
area (SASA) model. The last term is the absolute temperature T multiplied by entropy S con-
tributions (Genheden & Ryde, 2015). Polar and non-polar contribution to binding energy are
further detailed in the next subsections.
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(ii) Polar and non-polar solvation energy terms
The free energy of solvation, ∆Gsolv is calculated from two components, polar and non-polar
solvation energies (Genheden & Ryde, 2015) (see Equation 2.32). Polar solvation can be calcu-
lated by solving the PB linearly (Equation 2.33) when both ionic strength and solvent potential
are low and when asymmetric electrolytes are considered (Genheden & Ryde, 2015).
∆Gsolv = ∆Gsolv, polar +∆Gsolv, non-polar (2.32)
∇.ε∇φ =−4πρ0 + εvK2φ (2.33)
where, K2 = 8πe
2I
εvkBT
, V = solvent, I = ionic strength of the solution, it is defined as I = Z2C,
where, Z2 and C are charge and molar concentration of ion, respectively. When the solvent





The polar solvation term stated in Equation 2.31, was first developed by numerically solving
PB equation (Kollman et al., 2000). However, methods such as continuum-solvation are now
commonly used in calculating polar solvation in GB giving the name MM-GBSA (Genheden &
Ryde, 2015). Several works exist where the performance of both MM-PBSA and MM-GBSA
methods have been compared (Xu et al., 2013; Sun et al., 2014) with MM-PBSA showing
better performance (Xu et al., 2013) or similar results (Sun et al., 2014; Rastelli et al., 2010;
Sun et al., 2014) depending on the system studied. The effects of polar solvation on PB results
have been investigated. For example, it has been shown that the contribution of polar solvation
energy to the binding free energy in PB method is affected by the radii used. Other studies
have investigated other solvation methods such as GB and polarized continuum model (PCM),
and have found that for ligands with same net charge all methods (PB, GB, PCM) gave similar
results within 2-5 kJ/mol (Genheden & Ryde, 2015).
The non-polar solvation energy is directly related to the SASA (Genheden & Ryde, 2015; Sun
et al., 2014) using the Equation 2.35
∆Gnon-polar = γ×SASA+b (2.35)
Here, γ is the coefficient related to surface tension of the solvent and it varies from 0-4.2 kJ/mol
(Genheden & Ryde, 2015), b is the fitting parameter.
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(iii) Electrostatic term, Eele
In MM-PBSA, electrostatic term, Eele, is calculated using dielectric constant, ε . Originally,
MM-PBSA was calculated using a ε =1, although a large value has been suggested for improv-
ing the results (Genheden & Ryde, 2015). However, the optimal ε value has been observed
to depend on the nature of the binding pocket where a more charged pocket requires a large ε
value compared to a more hydrophobic pocket. The ε value ranging from 2-4 has been shown
to produce good results in many studies (Genheden & Ryde, 2015).
2.4.3 Limitation of MMPBSA
Despite of its popularity in estimating free energy of ligands bound to their macromolecules,
MM-PBSA method is limited due to poor precision. The method results into large standard
error deviation (Genheden & Ryde, 2015; Peräkylä & Nordman, 2001). Poor precision ren-
ders the method useless especially when one wants to compare results obtained from different
approach or when one compares the ligands with similar affinity (Genheden & Ryde, 2015).
Today, several suggestions have been attempted to reduce such limitation, one of the attempt
has been suggested to run many short independent simulation instead of a single long simula-
tion which can underestimate uncertainty in results (Genheden & Ryde, 2015). Some studies
have shown that, an equilibration of 100 ps and production of 100-200 ps of many independent
simulation i.e 20-50 ns can reduce the error and would be appropriate enough (Genheden &
Ryde, 2015).
2.5 Some examples of successful applications of molecular dynamics and related meth-
ods in drug discovery and design
2.5.1 The success and limitations of molecular docking
The preceding sections have discussed several computational methods used in drug discovery
and design. This section, discusses the practical application of molecular dynamics and related
methods in drug discovery and design. The applications of these method have brought great
success in drug design as some drugs discovered using these methods are now available in the
market and have been approved by relevant authorities. In this thesis the discussion focuses
more on the discovery of the Hsp90 inhibitors. The structure and function of the Hsp90 is
described in Chapter 1.
As described in Section 2.1, molecular docking is a popular computational chemistry shape
based method with high ability to predict the binding mode of ligands to their 3D macromolec-
ular active sites (Piaz et al., 2012; Abbasi et al., 2018; Saxena et al., 2010; Verdonk et al., 2003;
Stjernschantz & Oostenbrink, 2010; Vijesh et al., 2013; Mbatha, 2015; Ramı́rez & Caballero,
2016), but, it poorly estimates and ranks the binding affinity of ligand to their macromolecules
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(Shamsara, 2018; Warren et al., 2006). Docking is widely used in identification of protein bind-
ing pockets (Ruppert et al., 1997), drug discovery (lead optimization) (Piaz et al., 2012; Vijesh
et al., 2013), protein-protein interaction (Dominguez et al., 2003; Comeau et al., 2004; Tovchi-
grechko & Vakser, 2006) as well as in virtual screening (Verdonk et al., 2004; Cavasotto et al.,
2007) where a large number of small molecules are screened against a known 3D macromolecu-
lar target. Other areas where molecular docking is widely used include protein engineering and
enzymatic reaction mechanism (Mbatha, 2015). Molecular docking mostly helps to understand
the binding nature or orientation of ligand in the protein active site (Mbatha, 2015). During
molecular docking, the receptor-ligand binding energy is analyzed using molecular mechanics
(Mbatha, 2015) in Equation 2.36.
Ebinding = Etarget-ligand− (Etarget +Eligand) (2.36)
Results obtained from molecular docking are either supplemented with experimental studies
(Piaz et al., 2012; Gupta et al., 2015), molecular dynamics (Abbasi et al., 2018; Sha & Cao,
2015) and /or binding free energy calculation (Sha & Cao, 2015) to understand the stability of
the complex and estimate the binding affinity, respectively. Thus, several studies (Piaz et al.,
2012; Abbasi et al., 2018; Saxena et al., 2010) have employed molecular docking to understand
the binding modes of ligand inside the Hsp90.
The work by Piaz et al., (2012) investigated the inhibition of Hsp90 by a natural iminosugar
(+)-Lentiginosine (10) using biochemical methods and molecular docking. Molecular docking
revealed that iminosugar (+)-Lentiginosine binds to the middle domain of the Hsp90 differently
from the known ATP binding site (Piaz et al., 2012). Furthermore, Abbas et al. (2018) carried
out a combinations of pharmacophore modeling, molecular docking and molecular dynamics
to predict new inhibitors of Hsp90 based on isoxazole scaffold (Abbasi et al., 2018). Molecular
docking was performed on 16 training set to provide insight into their binding modes and in-
teraction with Hsp90. Of the 16 compounds, seven showed stability during MD simulation by
forming hydrogen bonds with amino acid Asp93 and Thr184 (Abbasi et al., 2018). In a similar
study Saxena et al. (2010), carried out pharmacophore modeling and molecular docking study
to identify new inhibitors of heat shock protein 90. Molecular docking helped to establish the
binding mode as well as the amino acids involved in Hsp90-ligand interaction (Saxena et al.,
2010). Docking estimated the binding affinity with a correlation coefficient of 0.699 to the
experimental IC50 values. It was established that, hydrogen bonding and hydrophobic interac-
tions were essential in Hsp90-ligand interaction (Saxena et al., 2010). Molecular docking and
pharmacophore modeling both predicated compound 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-
4-(4-piperidin-1-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethyl amide (11) to be the most
potent inhibitor of Hsp90.
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Sepehri and Ghavami (2018) conducted an in silico study employing molecular docking and
comparative molecular field analysis (CoMFA) to design new inhibitors of Hsp90 based on
tetrahydropyrido [4, 3-d] pyrimidine derivatives. In their study, three new molecules were
designed and all were docked to the ND-Hsp90 (Sepehri & Ghavami, 2018). Molecular dock-
ing helped in establishing the binding mode of the compounds into the ND-Hsp90. Hydroxyl
group on phenyl ring was observed to be important in forming hydrogen bonds with hydrophilic
residues and conserved water (Sepehri & Ghavami, 2018). The compounds were observed to
interact with Phe138 and Asp54 and Asp51 by forming π-sigma and hydrogen bonds (Sepehri
& Ghavami, 2018).
In some cases, molecular docking results have shown high correlation with experimental re-
sults. For instance, in an effort to discover and develop new potent inhibitors of Hsp90, Gutpa
et al., carried out molecular docking of mannich base against Hsp90 and then synthesized the
highly ranked compounds (Gupta et al., 2015). Synthesized compounds were then tested exper-
imentally for their anticancer and Hsp90 inhibition. Results showed that activity profile of the
synthesized mannich base compounds derived from 2,4-dihydroxyacetophenone/5-chloro2,4-
dihydroxyacetophenon correlated well with the docking results (Gupta et al., 2015). Results
from molecular docking showed that water molecule and amino acid residues Leu48, Lys58 and
Asn106 were necessary in forming hydrogen bonds contact, while amino acid residues Phe138,
Val150 and Val186 were important for hydrophobic interactions (Gupta et al., 2015). In another
work, Gupta et al., conducted molecular docking and experimental inhibition of Hsp90 using
schiff bases derived from 2,4-dihydroxy benzaldehyde/5-chloro-2,4-dihydroxy benzaldehyde
(Gupta et al., 2014). Compounds which showed lower binding energies were synthesized and
tested experimentally for their Hsp90 inhibition and anticancer activity using MTT (3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assays (Gupta et al., 2014). Docking
further showed that water molecule 903 and amino acid residue Asp93 and Asn51 were crucial
in forming hydrogen bonds (Gupta et al., 2014). Findings reported by Gupta et al. (2014) and
Gupta et al. (2015) shows that both mannich and schiff bases could be developed as potent
inhibitors of Hsp90 for cancer treatment.
Pan inhibition of Hsp90 inhibitors has remained the greatest challenge in the discovery and
development of potent inhibitor for this target. Several proposed inhibitors of Hsp90 inhibit
all the Hsp90 isoforms and hence present the greatest challenge. Pan inhibition of Hsp90 has
been associated with toxic side effects of many Hsp90 inhibitors due to the inhibition of hERG
activities (Peterson, 2012). Thus, in order to identify specific inhibitors of Hsp90 isoform, Sha
and Cao (Sha & Cao, 2015), carried out molecular docking, MD simulation and binding free
energy study of a benzolactam compound (12) against Hsp90 isoforms (Hsp90β/α and Grp94)
to further provide basis on isoform selectivity inhibition. The benzolactam compound was pre-
viously reported experimentally (Ernst et al., 2014) to possess isoform selectivity inhibition for
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Figure 6: Structure and binding mode of benzolactam (compound 12) when docked to Hsp90β and
Grp94. The figure is reproduced from Sha & Cao, 2015.
Hsp90β/α by >1000-folds against Grp94, however, the structural basis of its selective inhi-
bition remained not well addressed (Sha & Cao, 2015). Molecular docking provided detailed
information on its selective inhibition. Compound (12) bound differently in Hsp90 and Grp94
(Sha & Cao, 2015). The binding mode of cyclopentane moiety inside Hsp90 and Grp94 is
shown in Fig. 6. In both Hsp90β/α , the lactam moiety of compound (12) formed hydrogen
bond with amino acids Thr1834 and Asp93, respectively (Sha & Cao, 2015). Furthermore, the
cyclopentane moiety was buried inside the hydrophobic pocket formed by resides Ala55, Ile96
and Met98 (Fig. 6). The study by Sha and Cao (Sha & Cao, 2015) provided valuable informa-
tion towards designing novel and potent selective isoform inhibitors of Hsp90. The structures
shown in Fig. 6 were taken from the cluster of complex with lower binding energy. The cy-
clopetane moiety shows different orientation into Hsp90 and Grp94 which also provide basis
of isoform selectivity inhibition. Generally, molecular docking has shown to play an important
role in discovery of potent Hsp90 inhibitors.
Applications of molecular docking method is limited due to full flexibility of protein, accurate
estimation of binding affinity and inclusion of water molecules (few codes are able to include
structural water during docking calculations). Such limitations have necessitated the use of all
atom molecular dynamics (MD) simulation codes which allow full protein flexibility.
2.5.2 The success of molecular dynamics approaches
Earlier works on molecular dynamics simulations reported by Levitt and co-workers (Levitt
& Warshel, 1975) and McCammon and co-workers (McCammon et al., 1977) have provided
strong insight into the role of classical MD in simulating biological materials such as proteins
and nucleic acids (Levitt & Warshel, 1975; McCammon et al., 1977). In their works, they
showed how classical MD can be used to study folding and conformations of proteins and nu-
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cleic acids (Levitt & Warshel, 1975; McCammon et al., 1977). Over the recent past years, many
researchers have established that MD simulation has a great potential to overcome limitation of
static structure based drug design which is mostly applied in docking experiments (Sinko et al.,
2013; Kokh et al., 2011; Kim et al., 2018). Protein flexibility is one of the major limitation of
common molecular docking tools which (few of them) allow only side chain of the protein to
be flexible and this has remained a challenge (Sinko et al., 2013; Kokh et al., 2011; Kim et al.,
2018). One of the greatest promise of classical MD in structural based drug design is structural
flexibility of protein. Ensemble based docking has emerged as an alternative to static docking
(Lin et al., 2002; Amaro et al., 2008a; Lin et al., 2003; Chan et al., 2013; Kim et al., 2018) as
detailed in the next subsection.
2.5.3 Relaxed complex scheme
Protein flexibility plays an important role in computational drug design and development. Ac-
counting for receptor flexibility in drug design and discovery has become a subject of interest
among medicinal chemists, biophysicists and biochemists. Relaxed complex scheme or ensem-
ble based docking has become an important approach in addressing protein flexibility during
docking experiments (Lin et al., 2002; Amaro et al., 2008a; Lin et al., 2003; Chan et al.,
2013; Kim et al., 2018). In this approach, a crystal structure of a protein is subjected to a
long MD simulation for hundrends of nanoseconds. From the MD structure different snapshots
are extracted, clustered and then subjected to virtual screening or molecular docking experi-
ments (Lin et al., 2002; Amaro et al., 2008a; Lin et al., 2003; Chan et al., 2013; Kim et al.,
2018). Results from different structures are averaged to obtain improved results reflecting flex-
ible protein structure. This study has utilized RCS aiming at identifying Hsp90 inhibitors using
an improved ensemble based docking protocol.
Protein flexibility in drug design and discovery was first reported employing a RCS protocol
by the group of McCammon (Lin et al., 2002; Lin et al., 2003). The protocol has gained
popularity in structured based drug design (SBDD) where several research groups have used
the protocol to account for the protein flexibility in drug discovery regime (Chan et al., 2013;
Kim et al., 2018). The protocol has been extended to virtual screening of several compounds
(Totrov & Abagyan, 2008). In an effort to discover novel inhibitors of Hsp90, Kim et al.
(2018) employed an ensemble based docking and biophysical methods to identify potential
inhibitors of Hsp90 (Kim et al., 2018). Ensemble based docking identified four compounds
(13-16) as potential inhibitors of Hsp90. Biophysical studies of the four compounds corre-
lated with ensemble docking results. The two compounds (13,14) possessed anticancer activity
against MCF7 breast cancer cell, while all four compounds possessed strong inhibitory activ-
ities against A549 prostate cancer cell line (Kim et al., 2018). Hsp90 inhibition by the four
compounds was checked by measuring the mRNA levels in MCF7 cell. Hsp90 inhibition was
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found to be time dependent for all four compounds (Kim et al., 2018). The study by Kim et al.
(2018) has provided strong bases on developing new and potent Hsp90 inhibitors.
Despite of its success, RCS, still suffers from limitations apart from those of being based on
classical MD simulations which are subject to inadequate conformational sampling and force
field approximation (De Vivo et al., 2016; Durrant & McCammon, 2011). RCS depends on
docking scoring functions which sacrifice accuracy at the expense of achieving high speed
(Durrant & McCammon, 2011).
2.5.4 Application of free energies methods
Despite that several docking algorithms are optimized at the expense of time rather than accu-
racy, however, more accurate methods to predict binding affinity do exist but they are compu-
tationally demanding. Methods such as thermodynamic integration, free energy pertubation,
single-step pertubation as well as molecular mechanics Poisson Boltzmann (Generalized Born)
surface area (MM-PB(GB)SA) are commonly used in calculating binding affinity of ligands to
their receptors. In this thesis, TI and MM-PBSA methods by pointing out their success and
limitations are discussed.
Free energy calculations using TI are increasingly to variety of biological systems and have
aided towards understanding the association and dissociation of protein-ligand complex of in-
terest, in particular Hsp90 with its inhibitors or substrates (Ignjatović et al., 2016; Kawaguchi
et al., 2016). Recently, Kawaguchi and co-workers (Kawaguchi et al., 2016), carried out a
thermodynamic integration (TI) to investigate the association mechanism of N-terminal do-
main Hsp90 (ND-Hsp90) and ADP (Kawaguchi et al., 2016). They found that, the association
is driven by van der Waals forces of interaction while electrostatic destabilizes the association
(Kawaguchi et al., 2016). Furthermore, authors, found that, during the association process,
ADP is pulled by Lys69 from bulk region of the pocket and Lys112 at the surface entrance of
the pocket and finally pushed out by solvate water molecules in the binding site of ND-Hsp90
(Kawaguchi et al., 2016). Such association process provides a good basis towards understand-
ing the association of protein-ligand complexes as well as towards the discovery of novel ND-
Hsp90 inhibitors (Kawaguchi et al., 2016). In another work, the dissociation of ADP from
ND-Hsp90 was investigated by using both MD and TI approaches (Kawaguchi et al., 2013).
TI revealed the dissociation minimum distance of 0.8 nm with the free energy of -75.2 kJ/mol.
Although this binding free energy is contrally to the experimental binding free energy of -26.2
kJ/mol reported by Nilapwar et al. (2009) at 20 ◦C, the difference is due to the inconsistency
of the calculated value and the experimental free energy (Kawaguchi et al., 2013). The free
energy calculated by Kawaguchi et al. (2013) is the free energy difference with the reference
state and not standard state. Despite of the difference, the results reported by Kawaguchi et
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al. (2013), make sense in terms of estimating the binding free energy as a function of distance
from reference state. The dissociation of ADP from ND-Hsp90 was observed to be restricted
by amino acid Met98 as revealed by MD simulation (Kawaguchi et al., 2013), as the tail group
of ADP moves from inside to outside through the side chain of Met98 with a distance of 1.0
nm. Similar observation for ligand movement restriction by Met98 has been previously re-
ported (Immormino et al., 2006).
Flexibility of the ND-Hsp90 binding pocket has remained a challenge in discovering inhibitors
not only in experimental approaches but also in theoretical/computational approaches. Several
studies have reported the flexibility of ND-Hsp90 binding pocket to be one of the limitations
in identifying potential inhibitors (Ignjatović et al., 2016; Simunovic & Voth, 2012; Ribeiro
et al., 2018). In their work, Ignjatovic et al., (2016) carried out free energy calculation using
alchemical methods, docking and MM/GBSA to estimate the binding affinity of three sets of
ligands to Hsp90. The relative free energy was estimated by using the Multi-state Bennett
Acceptance-Ratio (MBAR) approach (Ignjatović et al., 2016). Despite the fact that alchemical
methods are known to be accurate in estimating the binding affinity (Su & Johnson, 2016;
Ytreberg et al., 2006; Aldeghi et al., 2018), free energy results for all sets of ligands were
rather disappointing and poorly correlated with the experiment and resulted into larger errors
of up 26 kJ/mol (Ignjatović et al., 2016). The reasons for such discrepancy were related to
high flexibility of the Hsp90 binding pocket which resulted to; different binding mode in the
crystal structure, exclusion and inclusion of structural water and inaccuracy of the molecular
mechanics (MM) force field to model the chemical variation of the ligands (Ignjatović et al.,
2016). Some of the compounds discovered as Hsp90 inhibitors using MD simulation related
methods are presented in Fig. 7.
2.5.5 Application of MD simulation in drug delivery systems
Molecular dynamics and related methods are now widely used in studying the interaction of
nanocarriers with their drugs. This subsection points out how molecular dynamics methods
have provided insight in studying the interaction of polymers such chitosan nanoparticles and
PAMAM dendrimer in drug delivery. The application of different computational tools to study
drug delivery systems based on PAMAM dendrimer has been highlighted in our previous work
(Shadrack et al., 2018). The current study discusses the application of molecular dynamics in
studying drug delivery system based on chitosan nanoparticle.
Polymeric based nanoparticles have shown a great potential in the biomedical field as drug de-
livery and diagnostic agents. In particular, chitin a 1,4-β linked polymer of N-acetylglucosamine
that is cheap and abundantly available in nature (Shan et al., 2014) has gained much attention














































Figure 7: Some of the new discovered Hsp90 inhibitors using molecular dynamics and related methods.
which is obtained by deacetylation process as shown in Fig. 8. Such a process makes chitosan
to have improved and desirable properties as a drugs delivery agent than chitin (Shan et al.,
2014).
Such improved and excellence properties includes; good biocompatibility, chemical stability,
low cost, improved solubility and low toxicity (Shan et al., 2014). The characterization of
chitosan-drug interaction for drug delivery system has been widely reported using both ex-
perimental (Sanyakamdhorn et al., 2013) and computational (Shan et al., 2014; Shen et al.,
2017) methods. Understanding interactions at atomistic level in nanoparticle-drug is of great
importance, however, such process is not trivial and rarely gives insights at the atomistic level
directly from experiments (Carr et al., 2018). Over the recent years, molecular simulations have
aided experimental results by providing fundamental insights into the interaction of host-guest
systems. Many successful examples now exist where classical molecular dynamics provided
insight at the molecular level to understand the interaction of chitosan and drugs in different
solvents (Shen et al., 2017; Razmimanesh et al., 2015; Rungnim et al., 2013). For instance,
Shan and coworkers, investigated the interaction of hydrophobic hydrophilic modified chitosan
nanoparticles using molecular dynamics simulation (Shan et al., 2014). In their study, MD sim-
ulation helped to establish that hydrophobic modified chitosan nanoparticle were suitable for



































Figure 8: Deacetylation process of chitin. (a) shows the chemical structure of chitin (b) the chemical
structure of chitosan.
with polynucleotide at molecular level was investigated using molecular dynamics (Shen et al.,
2017). Results presented in their work established and paved the way on how polynucleotides
interact with chitosan at different protonation states.
This subsection, highlighted few among many successful and usefulness of molecular dynam-
ics simulation in studying the interactions between chitosan and drug at atomistic level with
applications in drug delivery system. Such examples have, however, only based on the thermo-
dynamics aspects with little consideration (if any) on the kinetics and residence time of drug
unbinding. This provides a room to further explore the kinetic rate of drug unbinding with its
implication to drug delivery systems based on chitosan-drug interaction.
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2.5.6 Solution conformation of natural products: Curcumin as a model natural product
Natural products have played a great role in human history and have served as medicine for
treatment of many ailments, including malaria, tuberclosis, cancer and inflammation to men-
tion a few (Patsahan et al., 2017; Ilnytskyi et al., 2016). For example, curcumin, isolated from
Curcuma longa plant, is a well known and documented natural product used as colouring agent,
food spices and medicine (Patsahan et al., 2017; Ilnytskyi et al., 2016). Its biological activities
range from antiviral, antioxidant, antiiflammatory, anticancer and antidiabetics amongst others
(Patsahan et al., 2017; Ilnytskyi et al., 2016; Slabber et al., 2016). Although curcumin possess
broad biological activities, its clinical applications are limited due to its poor aqueous solubil-
ity (Hani & Shivakumar, 2014). Owing to its numerous biological properties and poor aqueous
solubility, curcumin was selected as a model natural products to investigate its solution confor-
mation at molecular level.
It is well documented that, clinical applications of many natural products, and in particular,
curcumin are limited due to poor aqueous solubility, chemical instability, low cellular uptake,
quick hydrolysis and short half-life (Patsahan et al., 2017; Ilnytskyi et al., 2016; Slabber et al.,
2016). In order to address such challenges, a natural product needs to be dissolved in appro-
priate solvents or need a delivery system which may increase solubility, half-life and cellular
uptake (Patsahan et al., 2017; Ilnytskyi et al., 2016; Slabber et al., 2016).
Chemists have well acknowledged that the biological activities of a natural product or small
molecule depends on several factors which includes: nontrivial response to solvents, fragment
conformation, charge distribution and molecular structure besides other factors (Slabber et al.,
2016; Ilnytskyi et al., 2016). Investigation of structural conformation helps in understanding
the pharmacological properties of a natural product in question. Despite the fact that, curcumin
has been studied for many years, its solution conformation has given little attention with few
studies been reported using computational and experimental methods (Hazra et al., 2014; Pat-
sahan et al., 2017; Ilnytskyi et al., 2016; Slabber et al., 2016).
Because of some limitation to experimental methods in investigating materials at molecular
level, computational simulation approaches have provided a better way of understanding be-
haviour of materials at molecular level. In order to understand the behaviour i.e configuration,
conformation, stability and orientation preferences of curcumin in different solvents, in this
thesis, computational methods in particular metadynamics an enhanced sampling method was
used to explore such properties and behaviour. In addition, as discussed in Chapter 1, Section
1.1.4 of this thesis, the role of solvents on residence time and kinetics of host-guest complex
are investigated using computation methods to provide the underlying information on how sol-
vents affects the interaction. Two solvents are used viz. DMSO and water, DMSO is a clinical
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relevance solvent and some drugs formulated with DMSO exist (Slabber et al., 2016).
2.6 Conclusion and way forward
This Chapter has discussed different computational methods employed in drug discovery and
design. The chapter started by discussing various computational methods from molecular dock-
ing, molecular dynamics, metadynamics and free energy methods (TI and MMPBSA). Some
successful examples where such methods have been applied in the field of drug design have
been highlighted. Although different docking protocols and molecular dynamics are used in
many studies, there is a lack of study which describes the effects of inclusion of water into dif-
ferent docking protocols such as docking to crystal structures with and without water, docking
to ensemble holo and apo protein structures with and without water. On the other hand, the use
of molecular dynamics to study the interaction of chitosan-drug interaction is well appreciated,
however, there is lack of studies (if any) which report the effect of different solvents on the
kinetics and residence time of drug unbinding. The effects of different solvents on conforma-
tion and kinetics of natural products is also an area in drug design which needs to be given
attention. Studies of heterogeneous interaction at crystal-water interface using molecular dy-
namics simulation in drug design has gained less attention. Many studies have focused on the
thermodynamics properties on drug binding, with less attention payed to kinetics, residence
time, interaction at the crystal structure-water interface and polymophism changes which have
a great implication to drug design.
In this study different protein-ligand docking protocols are explored. The thesis further reports
the effect of solvents on the conformation and kinetics of small molecules using curcumin as
a model molecule. The solvent effects on kinetics and residence time on host-guest unbinding
is also investigated using toussantine-A-chitosan complex as a model system. The next chapter






The X-ray crystallographic structure of Hsp90β (PDB ID: 3NMQ) (Yun et al., 2011) in com-
plex with EC-44 inhibitor was obtained from RCSB Protein Data Bank. For validation purpose,
the complexes of Hsp90α (PDB ID: 4EGK) (Austin et al., 2012), Grp94 (PDB ID: 3O2F) (Pa-
tel et al., 2013) and Grp94 (PDB ID: 1QY8) (Soldano et al., 2003) were also obtained from
RCSB Protein Data Bank (PDB). For molecular docking calculations the proteins and ligands
were prepared using FlexX (part of LeadIT) molecular docking software, BioSolveIT, GmbH,
German (Kramer et al., 1999). The binding site of the protein was examined from the crystal
structures using EC-44 as a reference ligand (Kramer et al., 1999) and finally confirmed by
X-ray data from the literature (Stebbins et al., 1997). After identifying the binding site, the
ligand was removed from the active site and the protein was subjected for virtual screening.
3.1.2 Validation of molecular docking protocol
Before inferring any prediction from the docking procedure it is important to understand its
limitations. For example, one of the limitation of docking methods to predict experimental
results, is the accuracy of the scoring function (David et al., 2005). One of the best known
approach to validate the docking program is its ability to retrieve the binding mode of known
drugs in the protein. In this study, root mean square deviation (RMSD) and experimental
binding energies were used to validate the docking scoring function. RMSD is used as the
measure to indicate if the binding mode is successful or not. If the RMSD is less or equal to 2.5
Å, then, the scoring function is able to reproduce and predict the binding mode for other drugs
(Brooijmans, 2009; Hevener et al., 2009). Ligands were extracted from their binding modes
and redocked again and their RMSD was assessed and presented in Table 1 in Chapter 4. This
validation confirms the goodness of the results reported in this thesis. In particular, the RMSD
of the redocked ligands was 6 2.5 Å. In a similar way, experimental data from literature (Baum
et al., 2009; Baum et al., 2010) obtained by using isothermal titration calorimetry method and
the calculated binding free energy reported in this thesis were compared and found to be in a
reasonable agreement with the correlation value r2 = 0.92 as shown in Figure 10 Chapter 4.
3.1.3 Virtual screening
Small molecules (drugs) used in this study were obtained from drug bank database, which com-
prise of more than seven thousands approved small molecules and macromolecules (Wishart
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et al., 2007). Small molecules were downloaded with their chemical structure in SMILES
(Simplified Molecular Input Line-Entry System). The SMILES were then converted into .sdf
and .mol file format. The Lipinski (Lipinski et al., 1997) rule of five (LRo5) was used in pre-
screening (filtering) the small molecules. A total of 2000 small molecules were obtained and
subjected to virtual screening against Hsp90β . Virtual screening was done by an in-house envi-
ronment in Mmcule with the Autodock Vina (Trott & Olson, 2010) docking program. Pyrrolo-
pyrimidine methoxypyridine (EC-44) a known Hsp90 inhibitor with a binding energy of −9.2
kcal/mol was used as a reference ligand. 26 approved drugs with binding energies less than
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Figure 9: Drug repurposing protocol employing the relaxed complex scheme used in this study.
3.1.4 Molecular docking with FlexX
FlexX (LeadIT) is a flexible docking method which employs an incremental construction (IC)
algorithm to dock ligands into the active site (Kramer et al., 1999). In FlexX, the ligand is de-
composed into many components, then, protein interactions guide the reconstruction (assemble
of ligands) into the active site by using various placement strategies (Kramer et al., 1999). Lig-
ands were docked into the active site. Docking calculations were performed on different types
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of conformations: crystal structure with and without water and receptor ensembles for apo and
holo structures from the MD simulation with and without water. For the crystal docking pro-
tocol, water was chosen using a cutoff of 6.5 or 10 Å from the center of mass of the reference
ligand EC44.
The binding free energy was calculated and assessed by using HYDE (HYdrogen bond and
DEhydration energy in protein-ligand complexes) scoring function (Schneider et al., 2013) as
described in Chapter 2. During docking, a total of ten poses were generated and assessed for
their binding energies. Poses with lower energy for each docked conformation were recorded
and averaged as mean relaxed complex (RC) binding energies.
3.2 Molecular dynamics (MD) simulations
3.2.1 Protein-ligand interactions
Molecular dynamics simulations were carried out with GROMACS (GROningen MAchine for
Chemical Simulations) Ver. 5.1.2 (Abraham et al., 2015) with the amber03 force field (Wang
et al., 2004). The crystal structure of the Hsp90 (PDB ID: 3MNQ) (Yun et al., 2011) with
ligand removed, was used to generate apo structures for the relaxed complex scheme. Protein
topologies were generated using GROMACS while ligands topologies were generated using
antechember (Wang et al., 2004). A total of four proteins system simulations were performed
corresponding to apo and holo (bound) systems. The systems were solvated with the TIP4P
(Horn et al., 2004) water model and sodium ions were added to neutralize the system. All the
systems were energy minimized using steepest descent algorithm with position restraints. En-
ergy minimized systems were then equilibrated for 5 ns then followed by a production run for
250 ns and 100 ns for apo and holo systems, respectively. At the equilibration stage, the tem-
perature and pressure was maintained using the Berendesen method (Berendsen et al., 1984).
For the production stage, Parinello-Rahman (Parrinello & Rahman, 1981) was employed for
pressure coupling at 1 bar and v-rescale (Bussi et al., 2007) was used for temperature coupling
at 300 K. Particle Mesh Eward (PME) (Cheatham et al., 1995) was used to treat the long-range
electrostatic interactions. Covalent bonds were constrained by using LINCS algorithm (Hess
et al., 1997) and a time step of 2 fs was used for all calculations. For all systems (apo and holo
structures), after the protein reached equilibrium, configurations were sampled every 2 ns for
the docking experiments. A total of 50 configurations were used for the docking.
3.2.2 Curcumin in bulk solvents
The crystal structure of curcumin was extracted from the Cambridge Crystallographic Data
Center. A single molecule of curcumin was differently solvated with pre-equilibrated sol-
vents viz: 1620 TIP4P (Jorgensen et al., 1983) water molecules, 682 methanol (MeOH), 572
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dichloromethane (DCM), 505 carbon tetrachloride (CCl4) and 402 dimethyl sulfoxide molecules,
to have five different systems. The solvated systems were energy minimized using steepest de-
scent algorithm to remove any overlap of the atoms from the staring coordinates. All systems
were then equilibrated at NPT ensemble as previously reported for a single curcumin in water
(Ilnytskyi et al., 2016) at a temperature of 300 K and 1 bar using a time step 0.1 fs for 500 ps.
A production run was carried at NPT ensemble with a temperature of 300 K and 1 bar for 5 ns
using Parrinello-Rahman barostat (Parrinello & Rahman, 1980). Bonds were constrained using
LINCS (Hess et al., 1997), while Particle Mesh Ewald (PME) (Darden et al., 1993) methods
were used for handling long-range electrostatic interactions. All simulations were performed
using GROMACS code (Abraham et al., 2015) version 2016 with OPLS-AA (Jorgensen et al.,
1996) force field. The configuration from MD simulation was used for metadynamics simula-
tion.
3.2.3 Chitosan-TouA supramolecule in solvents
For host-guest interactions, the initial structure of chitosan was obtained from PubChem database
and functionalized with triphosphate (TPP) groups. Group functionalization and energy opti-
mization were done using Avogadro (Hanwell et al., 2012) employing the MMFF94 force field.
The structure was then subjected to molecular docking to obtain the chitosan-TouA complex.
Docking calculations were performed using ArgusDock docking engine (Oda et al., 2007) to
obtain the complex with the lowest binding energy for MD simulation.
MD simulation was done using GROMACS 2016 (Abraham et al., 2015) employing GRO-
MOS 54a7 (Schmid et al., 2011) force field. The topologies were generated using PRODRG
(Schüttelkopf & Van Aalten, 2004). All systems were solvated in explicit solvents, DMSO and
SPC (Gereben & Pusztai, 2011) water model . All the systems were energy minimized using
steepest descent algorithm with position restraints. The systems were equilibrated at NVT for
500 ps and NPT ensemble for 1 ns, respectively, then followed by a production run for 140 ns.
During the equilibration stage, both temperature and pressure were maintained using Berendsen
method (Nosé, 1986). For production stage, Parinello-Rahman (Parrinello & Rahman, 1981)
and v-rescale (Bussi et al., 2007) were used for pressure and temperature coupling at 300 K,
respectively. Particle Mesh Ewald (PME) (Cheatham et al., 1995) was used to treat long-range
electrostatic interactions while covalent bonds were constrained using the LINCS (Hess et al.,
1997) algorithm, a time step of 2 fs was used for all calculations. The MD configuration was
then used for metadynamics simulation to investigate the kinetics and residence time.
3.3 Well-Tempered metadynamics (WT-MetaD)
Solvent-solute interaction, drug unbinding kinetics and residence time were investigated using
well-tempered metadynamics simulation (Barducci et al., 2008) as described in Chapter 2.
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During WT-MetaD the biasfactor and Gaussian height were set to 10 and 1.2, respectively, the
sigma values were obtained from short unbiased MD simulation. The following CVs were
chosen to describe the conformational changes of curcumin in vacuum and bulk solvent, CV1:
the keto-enol distances, CV2: end to end distance, CV3: torsional angles and CV4: number
of hydrogen bonding. While, for chitosan-TouA complex interaction, the following CVs were
used, CV5: minimum distance between chitosan and TouA selected from specific groups for
both chitosan and TouA, CV6: coordination number and CV7: torsional angle were used to
describe the unbinding process in different solvents. All WT-MetaD and free energy analyses
were done using plumed plugin for MD simulation version 2.4 (Bonomi et al., 2009).
3.3.1 Residence time (τAB) and koff calculations
In this thesis, drug residence time from state A to B (τAB) is defined as the time taken by
TouA to reach the solvent-exposed surface of chitosan from the bound state. A dmin > 0.6 nm
was used as a criterion for TouA to have completely unbound and solvent-exposed as at this
distance there is no interaction between chitosan and TouA. The time exchange from state A to
B and the transition state/activation barrier are denoted as τex and TS, respectively. Then, τAB
for the unbinding process that is from bound state A to unbound state B in the two solvents is
computed as:
τAB = τex · exp(B(T S−FA)) (3.1)
where B is the Boltzmann constant which is 2.6 kJ/mol and FA is the free energy for bound
state.
3.4 Binding free energy calculated by MM-PBSA
The MM-PBSA calculations were applied for three complexes of Hsp90-pitavastatin, Hsp90-
ezetimibe and Hsp90-vilazodone obtained from the MD simulation runs. The binding free
energy was performed using g mmpbsa tool implemented in GROMACS (Kumari et al., 2014).
A total of three hundred equally spaced snapshots were obtained from a single MD run, water
and counterions were removed before the calculations started. In this implementation, the
∆EMM calculated in gas phase is the total of van der Waal and electrostatic interaction energies.
The ∆Gsolvation is calculated as the sum of polar and non-polar. The polar part (∆GPB) was
calculated by linearly solving the Poission-Boltzmann equation, with a grid spacing set to 0.5
Å. The exterior dielectric constant (ε) was set to 80 and different values for solute dielectric
constant (ε) =1,2,3,4 were used. The non-polar (∆GSASA) was determined using the solvent
accessible surface area (SASA) with a gamma value set to 0.0226 and calculated as 0.0226 x
∆SASA. In g mmpbsa all the energy terms are calculated separately and then added up to obtain
the contribution of each residue to the binding energy.
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3.5 Thermodynamic integration
In order to further accounts for the effects of solvents on chitosan-TouA stability, binding free
energy based on thermodynamics integration (TI) was performed. TI is one of the most effec-
tive equilibrium approach for calculating the binding free energy (Kirkwood, 1935; Ytreberg











where 〈....〉dλ represents an ensemble average at different values of λ . TI was performed on
21 equally spaced λ value of 0.0, 0.05, .....0.95, and 1.0. The first 500 ps were discarded for
equilibration, then Equation. 3.2 was used to estimate the data using a trapezoidal rule. The




4.1 The role of water and conformational fluctuations in Hsp90 in response to inhibitors
4.1.1 Molecular docking benchmark and validation
Before embarking into molecular docking simulations, one has to validate the method used if
it can produce reliable results. In this thesis, RMSD as well as comparison to experimental
data were used to validate the docking method as described in Chapter 3. The RMSD of the
redocked ligands and their binding energies as compared to experimental data are presented in
Table 1 and Fig. 10. Both RMSD and correlated binding energies showed that the method is
reliable in reproducing docking poses and can be trusted for other docking experiments.
Table 1: RMSD (Å) of the X-ray crystal structure and redocked ligands of the best conformations in
their active sites.
PDB Code Complexes FlexX RMSD (Å)



























Figure 10: Correlation (r2 = 0.92) of experimental and calculated binding free energy (kJ/mol).
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4.1.2 Molecular dynamics and conformation changes of Hsp90β active site
Accommodating full protein flexibility in docking calculations is challenging. Many dock-
ing programs do not allow full protein flexibility during molecular docking calculations. To
adopt full protein flexibility, the RCS approach was employed. 250 ns run molecular dynamics
simulation of Hsp90β was carried out to reveal the most flexible parts of the protein, to gener-
ate flexible receptor ensembles for molecular docking and to understand flexibility/movement
of residues and water molecules in the active site. It was hypothesized that pocket fluctua-
tion would result in different binding modes of the drugs and changes in numbers of water
molecules. Some drugs showed different binding modes and energies when docked to different
MD snapshots. Some snapshots were observed to have large ∆G, while some snapshots had
small ∆G which resulted in a large variation of the binding free energies. The effects of protein
pocket fluctuations on binding free energies (∆G) of drugs have also been reported in some
studies which involved docking to MD snapshots (Hernández-Rodrı́guez et al., 2016).
The backbone RMSD of the free (unbound state) Hsp90β (Fig. 11a) equilibrated after 100 ns
and remained stable until the end of the run with an RMSD mean value of 0.26 nm. Further
analysis showed large fluctuations corresponding to helix 4 (α4) with amino acids from 105 to
114 as shown in Fig. 12. Fluctuations on helix 4 have also reported in the literature (Barker
et al., 2010; Prodromou et al., 1997). Hsp90 has been reported to adopt conformation change
at ATP pocket on the N-terminal domain, and it was reported that the nature of such conforma-
tion remained unknown (Barker et al., 2010; Krukenberg et al., 2011; Prodromou et al., 1997).
High fluctuations of helix 4 also affect the binding pocket, and this has remained one of the
challenges in designing Hsp90 inhibitors (Barker et al., 2010; Krukenberg et al., 2011; Prodro-
mou et al., 1997). The flexibility of this region is also reported for Hsp90α (Yan et al., 2008).
Besides RMSD the root mean square fluctuation (RMSF) of the protein was calculated. The
RMSF indicated more oscillation/fluctuations in the region with amino acid residues 60-75,
120-130 and 165. Such fluctuations were less than 0.2 nm (Fig. 11b). Other regions involved
in the binding sites remained stable.
The N-terminal domain (NTD) of the Hsp90 contains 226 amino acid residues made up of α
helixes and β strand sheets. The α helixes (H2, H4, H7) and Loop1 constitute the ATP binding
pocket and make up the wall of the ATP pocket, while the bottom is made up of the antiparallel
β strand sheets (β3, β4, and β7). The entrance diameter of the ATP binding pocket has a
diameter of 12 Å, depth 15 Å and 8 Å midway diameter as it narrows down (Kawaguchi et al.,
2016; Stebbins et al., 1997). The entrance surface of the pocket is made up of polar solvent
accessible amino acid residues Lys58, Lys69, Asn106 and Lys112. As it narrows down the
pocket it is formed by the hydrophobic, charged and polar amino acid residues: Leu48, Asn51,
Asp54, Ala55, Ile91, Asp93, Ile96, Gly97, Met98, Asn106, Leu107, Gly135, Phe138, Val150,
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RMSF of free Hsp90 beta
(b)
Figure 11: (a) General RMSD of free Hsp90β over 250 ns, the inset shows sampling time from 100-250








Figure 12: Fluctuation of alpha helix 4 with amino acids from 105-114. Light blue shows the movement
of alpha helix 4 from its original position at the beginning of the simulation.
4.1.3 Relaxed complex scheme (RCS)
To gain more understanding on the role of protein flexibility and water in molecular docking,
a relaxed complex scheme (RCS) approach defined in Fig. 9 was used. All 26 drugs obtained
from virtual screening were docked to protein conformations (receptor ensembles) extracted
from the molecular dynamics simulation. Figure 13 shows the docking results of drugs docked
to the X-ray crystal structure and MD snapshots with and without water for some of the drugs.
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(a) (b)
Figure 13: (a) Sensitivity of drugs when docked to crystal structure without water (dark blue), with water
cut-off 6.5 Å (red) and water cut-off 10 Å (yellow). (b) Sensitivity of drugs to RC structures
with and without water.
Docking calculations of all 26 drugs to X-ray crystal structures with and without water showed
different binding energies (Fig. 13a). Some drugs showed lower binding energies when docked
to crystal structure with water as compared to without water. For example, trovafloxacin
showed a difference of −23 kJ/mol for a crystal structure with and without water. The large
difference in the binding energy could be explained by the nature of the drug as it contain
more hydrophobic groups which would find it unfavourable to have water molecules in the
pocket during molecular docking and hence less binding energy for crystal structure with wa-
ter. Similar reasons hold for drugs such as imatinib and idelalisib which the inclusion of water
molecules make the binding energy less favourable and displayed a large difference in binding
energy. Some drugs did not show significant different in energy when docked to protein with
and without water.
The sensitivity of results to the crystal structure by including more water by changing the cut-
off tha is 6.5 and 10 Å was also investigated. The criteria for choosing a 6.5 Å was from
the reference molecule EC44, a co-crystallized inhibitor of Hsp90. The cut-off of 10 Å was
decided to understand if the inclusion of more water will have effects on the binding free en-
ergies. Docking to the crystal structure with water using a criteria cut-off of 6.5 and 10 Å
showed similar binding energy except for vilazodone, etravirine and domperidone (Fig. 13a).
Using vilazodone as an example, it can be said that the inclusion of several water has effects on
the binding energy of drugs and different drugs require different number of water for optimal
functioning (Santos et al., 2009). When vilazodone was docked using criteria of 6.5 Å lower
binding energy of −44 kJ/mol was obtained, however using a 10 Å cut-off criteria the binding
energy reduced to −29 kJ/mol.
When docking was performed using receptor ensembles with and without water small differ-
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ences in binding energy were recorded as shown in Fig. 13b. In some few cases water showed
an effect to some drugs, for instance, docking of dicoumarol showed lower binding energy
when docked to receptor ensemble with water compared to receptor ensembles without water.
Other drugs showed that water-mediated their interaction with protein while in other drugs,
water did not cause changes in binding energy. Some drugs, for instance, trovafloxacin, be-
haves in a peculiar manner, when it was docked to receptor ensembles with and without water
did not show a difference in binding energy, however, when docked to crystal structures large
differences in energy is observed. In few cases, drugs showed a similar trend for docking to
receptor ensembles and crystal structures with and without water. In their study, Santos et al.
showed that the effect of water on mediating protein-ligand interaction depends on the nature
of drug and protein conformation (Santos et al., 2009). While some studies (de Graaf et al.,
2006) have shown that water does not improve the docking energy of drugs, in this study it has
been found that, the effect of water depends on the nature of drugs and the conformation of the
protein. In general, it is observed that there is sensitivity of docking results when using crystal
and ensemble structures whereas, RCS seems to reduce the sensitivity of the docking results
with or without water.
4.1.4 Protein-ligand complex MD simulation
In order to gain more understanding on the stability of the docked drugs and the protein-ligand
complex, a molecular dynamics simulation was performed on the three drugs; ezetimibe, vi-
lazodone and pitavastatin to understand their dynamics inside the Hsp90 pocket over the sim-
ulation time. The three ligands selected were least sensitive to the docking protocols. MD
simulations for each protein-drug was monitored by checking the energetics and structural
properties of each complex for the whole simulation period of 100 ns. The structural stability
of the complexes was examined by the root mean square fluctuations (RMSF) and the distances
between the protein and the drugs. The following subsections present and discuss the residue
fluctuations induced by the ligand upon binding as well as the minimum distances between the
protein and drugs.
4.1.5 RMSF analysis
In order to capture detailed information on residue fluctuations induced by the ligand upon
binding, the RMSF difference between holo and apo protein is computed and presented in Fig.
14. One can see that all the drugs induced conformational changes to the residues but to differ-
ent extent. For example, in all structures one can observe residue fluctuations at the region with
residues from 20-40, 120-140 and 170. Residue fluctuations for vilazodone and pitavastatin
at the region from 20-40 exhibit similar nature with little changes compared to ezetimibe. On
closer look, ezetimibe and vilazodone shows fluctuations at the region from 60-70, which are
not observed in pitavastatin. The region made up of 120-140 and 170 residues shows similar
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fluctuations for pitavastatin and vilazodone which are not observed in ezetimibe.
In order to provide a predictive picture on the origin of these effects for the three drugs an illus-
tration of protein-ligand interaction complexes is presented in Fig. 15. It is observed that the
region from 20-40 residues is composed of the N-terminal loop and beta sheet 1 (β1), high fluc-
tuations at the beginning are expected due to high fluctuation of the loop. It is further observed
that, all drugs interact with alpha helix (α1) region made up of residues 22-36. Vilazodone and
pitavastatin show similar fluctuations which are not observed to ezetimibe, this is because both
vilazodone and pitavastatin are seen to bound near these residues and enhance fluctuations as
indicated in Fig. 15. However, ezetimibe is hanging up between loop (L4) and loop 5 (L5) and
is not able to interact with regions formed by residue 120-140, instead it interacts with alpha
helix 3 (α3).
Figure 14: RMSF differences of holo and apo protein. Vilazodone is shown in black colour, ezetimibe
in blue and pitavastatin in red colour.
(a) (b)
Figure 15: Binding orientations of the two drugs inside the Hsp90 pocket. (a) is the binding mode for
ezetimibe and (b) is the binding mode for pitavastatin.
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4.1.6 Minimum distances between ligands and the protein
In order to provide quantitative information of the movement of the drugs inside the protein
pocket, the minimum distance between the ligands and the protein was measured. Figure 16
shows the minimum distances of each groups of the ligand during the simulation time. For
clarity, group 1 is coloured black, group 2 is coloured red and group 3 is colored in blue as
indicated in the left pannel of Fig. 16. A general observation for all ligands is that, pitavas-
tatin shows the smallest minimum distance of less than 0.25 nm for all groups compared to
vilazodone and ezetimibe. The reason for this is that, pitavastatin is buried inside the pocket
and it interacts with the residues formed by alpha helix 1 (α1), 4 (α4) and (α5). On the other
hand, the two groups of vilazodone shows similar distance with group 3 being larger. A larger
distance of group 2 and 3 is attributed by the fact that these two groups are more exposed to the
solvent and are freely to move while group 1 is buried inside and its movement is restricted.
Group 3 of ezetimibe also displays large distances compared to the other groups as it points to
the entrance of the pocket and is exposed to the solvent. However, the two groups point towards
the beta sheets (group 2) and helix 4 (group 1) where their movement is restricted.
4.1.7 Holo RCS cross docking
The previous subsections discussed how the three drugs change protein conformation and the
fluctuations of the drugs in the protein. In this subsection, the cross docking experiment on
holo protein structures obtained from the apo docking experiment is discussed. Cross docking
refers to the process of docking a ligand to a protein containing different molecule (Sutherland
et al., 2007). In holo cross docking, all the drug candidates are removed from their bound state
and then each ligand is docked to three different protein ensembles from holo-vilazodone, holo-
pitavastatin and holo-ezetimibe. From cross docking experiment it is observed that, holo struc-
ture of pitavastatin possessed lower binding energy close to crystal structure (Fig. 17). Lower
binding energy of the holo structure of pitavastatin is explained by its binding mode inside
the protein. As depicted earlier in Fig. 16, minimum distance analysis shows that pitavastatin
has a smallest distance for all the groups suggesting that it is buried inside the protein pocket
and enhances little fluctuation to the protein. However, this is not observed for vilazodone and
ezetimibe, for example, groups 1 and 2 of vilazodone and group 1 of ezetimibe show larger dis-
tance suggesting that they are not buried and hence resulting to large fluctuation of the protein.
Such large fluctuations of the protein reduce the ability of the ligand to correctly bind into the
active site hence less binding energy is obtained.
4.1.8 Binding free energy calculated by MM-PBSA
Binding free energies calculated by MM-PBSA are effective in complimenting results obtained
from docking and MD simulation experiments. In this thesis, the binding free energy for the
three complexes was calculated using MM-PBSA method. Although the method is effective in
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Figure 16: Minimum distances between protein and the three ligands with their respective groups.
Colours shown on the minimum distance (left panel) represents the groups for each ligand
shown in the right panel. For all ligands group 1 is shown in black, group 2 in red and group
3 in blue.
estimating binding free energy in protein-ligand interactions, accuracy of the results obtained
by this method depends on solute dielectric constant (ε), nature of the protein active site and
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(a) (b)
Figure 17: Binding energy of 3 drugs in different holo structures (a) Docking into holo structures of
vilazodone (V), pitavastatin (P) and ezetimibe (E) without water (b) Comparison in binding
energy between the crystal structure and holo structure of pitavastatin.
length of the simulation time, usually, a smaller time is convenient. In this thesis, the binding
free energies were calculated from a single trajectory. The convergence of the free energies for
the complexes is presented in Fig. 18, as has shown in previous reports (Hou et al., 2010) that
the short MD run usually yields good results when compared to long MD run, in this work a
short MD run also yielded good results compared to long simulation. Furthermore, different
values for solute dielectric constant (ε) ranging from 1-4 were tested and the ε = 4 yielded rea-
sonable result. This is because of the nature of the binding pocket which contains hydrophobic
and charged residues as it narrows down and such properties require large value of ε . Table 2
shows the binding free energies obtained by MM-PBSA. The results suggest a strong binding
affinity for pitavastatin, followed by ezetimibe. However, a weaker interaction for vilazodone
complex was observed. The MM-PBSA results further support the RCS and MD simulation
results where pitavastatin complex shows to be more thermodynamic stable. Electrostatic and
van der Waal forces play an important role is stabilization of the complexes, in pitavastatin
electrostatic interaction highly contributes to stabilization of the complex. This is in agreement
with the MD results where pitavastatin is burried and remain stable in the Hsp90 pocket. In
addition, non-polar energies also contribute to stabilization of the Hsp90-pitavastatin complex
when compared to other complexes (Table 2). The observed larger error values is due to the
intrinsic properties of MM-PBSA method which result into large errors. Larger error values
in MM-PBSA have also been observed in previous reports (Peräkylä & Nordman, 2001). In
addition, large errors could also be attributed by large conformation changes at the ATP binding
pocket as previously observed for the docking results. The binding free energies obtained from
MM-PBSA further suggests that pitavastatin is the most stable and can bind strongly to inhibit
Hsp90 activities.
The energy term contributions listed in Table 2 show that van der Waals (∆EvdW), electrostatic
(∆Eele) and non-polar (∆Enon-polar) favorably contribute to the binding free energy, while polar
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energy terms (∆Epolar) are repulsive and unfavorably contribute to the binding free energy for
all ligands. Comparing the energy term contributions, one can see that the ∆EvdW energies are
larger and correlate with the size of the ligand i.e pitavastatin with topological polar surface
area of 90.6 Å2 is larger than ezetimibe whose topological polar surface area is 60.8 Å2. Large
size of hydrophobic molecule has been also observed to largely contributes to ∆EvdW energy
terms (Weis et al., 2006; Kuhn & Kollman, 2000). The ∆Enon-polar energy terms are observed
to be generally small but with correlation to the size of the ligand. The large value for ∆EvdW
energy is ascribed to the nature of the protein active site and the chemical nature of the ligands.
The Hsp90 active site contains charged and hydrophobic residues as it narrows down the active
site, the ligands also have more hydrophobic groups that are interacting with the protein. As
an example, Fig. 16a-b, shows that the more hydrophobic groups in pitavastatin are more
buried and interacting with the hydrophobic residue of the protein pocket. Thus, the interaction
between Hsp90 and ligands is more dominated with hydrophobic ∆EvdW interactions. On the
other hand, it can be said that polar groups of the ligand did not find adequate bonding terms
in the protein active site. Large ∆EvdW and repulsive or unfavorable ∆Epolar contribution to the
binding energy in Hsp90 has also been previously reported for more hydrophobic molecules
(Sha & Cao, 2015). Other studies have also reported large domination of the ∆EvdW energy
terms and the reason for such domination was the nature of the small molecules where the
charged molecules were observed to have large domination of the ∆EvdW energy terms and
resulted to more repulsive polar energy terms for biotin molecules binding to avidin protein




















































Figure 18: Convergence of binding free energies at different snapshots for ezetimibe and pitavastatin-
Hsp90 complexes calculated by MM-PBSA method, (a) ezetimibe and (b) pitavastatin.
Table 2: Relative binding free energies (kJ/mol) from MM-PBSA decomposition.
System ∆EvdW ∆Eele ∆Epolar ∆Enon-polar ∆Ebinding
Hsp90-ezetimibe −123.3 −45.3 142.4 −14.8 −41.1 ± 17
Hsp90-pitavastatin −222.2 −48.9 142.6 −22.5 −53.2 ± 20
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4.2 Solvent effects on drug interaction and conformation
This section presents and discuss the effects of different solvents on the properties of drugs/small
molecules in bulk solvents. In particular the section focuses on discussing the properties and
conformation of curcumin in bulk solvents and solvent effects on drug kinetics and residence
time using chitosan-TouA complex as a model system. The thesis begins by discussing the
properties and conformation of curcumin in bulk solvents.
4.2.1 Properties and conformation of curcumin in bulk solvents
Curcumin (Fig. 19), is a natural product derived from rhizome roots of the Curcuma longa
plant. Curcumin exists in keto-enol tautomerism. In its crystallographic form, the enol tau-
tomer is the most stable (Ilnytskyi et al., 2016; Patsahan et al., 2017; Slabber et al., 2016) and
is of most interest in this study. Since drug formulation takes place in organic solvents, under-
standing solution conformation of curcumin is an important step towards designing curcumin
formulation for various biological applications. In this thesis, metadynamics, an enhanced














































Figure 19: Chemical structure of curcumin molecule. Keto form of curcumin is indicated in top (a) and
the enolic form is below (b).
4.2.2 Curcumin in vacuum
To account for the effects of solvent in curcumin conformation and orientation, the behaviour
of curcumin in a vacuum is investigated by biasing keto-enol distance, ring-ring distance and
spacer dihedral angle connecting the two rings. The thesis begins by describing the free energy
profile of the keto-enol distance and orientation preferences in a vacuum. Figure 20 (a) shows
the 1D plot for keto-enol distance with three energy minima at 0.19, 0.37 and 0.5 nm. The
free energy minima at 0.19 nm correspond to the enolic hydrogen pointing towards the keto
oxygen. The free energy minimum at 0.37 and 0.5 nm corresponds to the enolic hydrogen of
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the cis and trans conformation pointing towards and away from the keto oxygen, respectively.
The tendency of enolic hydrogen to point towards keto oxygen is expected due to strong in-
tramolecular electrostatic interactions between the enol hydrogen and keto oxygen.
The ring-ring distance is obtained by measuring the center of mass distances of the two rings.
The ring-ring distance shows flat free energy with a minimum at 0.6 to 0.8 nm (Fig. 20b).
A deep minimum with free energy at a distance of 1.17 nm is observed which suggests that,
although there is a bent conformation, curcumin exist in a stretched conformation in a vacuum.
The observed distances and conformation changes are due to dihedral angle changes at the
spacer region connecting the two rings formed by atoms 8, 9, 10, 11 and 12, 11, 10, 9 and are
named as A1. The second dihedral angle group near the rings is formed by atoms 10, 9, 8, 7
and 10, 11, 12, 13 these dihedral angel are named as A2.
To gain further understanding of the origin of these conformation changes of curcumin in a
vacuum, dihedral angle distribution at the spacer region are analysed and presented in Fig.
20c and d. The dihedral angle at the spacer region A1 shows a minimum at φ = 0 and φ =
± 3 rad, indicating the presence of both cis and trans conformations. However, the dihedral
angle at A2 shows the minimum at φ = ± 3 rad showing the presence of trans-conformation
only. The distribution of dihedral angles suggests the presence of three conformations viz trans-
trans, trans-cis and cis-cis conformations. The next subsection discusses the effect of different
solvents on curcumin conformation and orientation preferences.
4.2.3 Curcumin in solvents
This subsection discusses the conformation and orientation preferences of a single curcumin
molecule in bulk solvents viz. water, methanol (MeOH), dichloromethane (DCM), dimethyl
sulfoxide (DMSO) and carbon tetrachloride (CCl4). First, the discussion begins by exploring
the 1D free energy profile for curcumin keto-enol distance in different solvents. The free en-
ergies are computed from the converged time dependence system for both keto-enol distances
and end to end distances. As an example, appendix 36 shows the diffusivity and convergence
of the systems for end to end distances in the studied solvents. The discussion begins by ex-
ploring the free energy obtained by biasing the keto-enol distance. Figure 21 and Table 3 show
the free energy profiles and the difference in free energy (∆F) values for keto-enol distances in
solvents, respectively. As shown in Fig. 21, the effect of solvents is manifested by different
minimum depth for the keto-enol (H28-O19) distances. DMSO a solvent where curcumin dis-
solves shows a small difference in ∆F value followed by water, CCl4, MeOH and DCM which
shows a large ∆F value (Table 3). The small ∆F value in DMSO and water explains the ten-
dency of enolic hydrogen to point outward the keto oxgyen group. As an example, in water
due to its electronegativity tendency, water would prefer to form intermolecular hydrogen bond
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with the enolic groups causing a C-O bond rotation which results for the enolic group to prefer

































































Figure 20: a-c, 1D conformation of curcumin in vacuum. (a) keto enol distance, (b) ring-ring distance,
(c) Dihedral angle distribution of the spacer connecting the two rings of curumin in vacuum.
d-e, 2D free energy landscape with representative snapshots for cis-trans conformation (d
= 0.19 nm), cis-cis conformation (d = 0.37 nm) and trans-trans conformation (d = 0.5 nm)
labeled as 1, 2 and 3, respectively.
This is contrary to less polar solvents and in vacuum where a large ∆F value is observed as a re-
sult of intramolecular hydrogen bonding interaction between the keto-enol groups. On the other



























Figure 21: 1D free energy for keto-enol distances in different solvents. The effect of solvent is mani-
fested by different minima.








These results suggest that curcumin with enolic hydrogen pointing towards keto oxygen is the
most thermodynamic stable in organic solvents capable of solubilizing it. Although there is
lack of experimental data on the solution conformation of curcumin except that of Slabber and
co-workers, the present result provides basic information on understanding the solution behav-
ior of curcumin in different organic solvents. Previous works on curcumin model studied by
standard molecular dynamics, for example, Pizio et al. (2017) using OPLS-UA force field ob-
served two maxima of curcumin in methanol at 0.19 and 0.37 nm for the keto-enol distance,
while Samanta and Roccatano (2013) using GROMOS96 force field did not observe the second
maxima at ≈ 0.4 nm in methanol.
To understand the effects of solvent on the end to end distance, the end to end distance was
biased by defining as the distance between the centers of mass of carbon composing the rings
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and results are presented Fig. 22 and Table 4. The free energy profiles for all solvents show
minima at 0.9 and 1.17 nm but with varying depth for bent and stretched conformation. To
understand the influence of solvent on curcumin conformation, the free energy difference (∆F)
for all solvents presented in Table 4 shows that polar solvents such as water, methanol and
DMSO have smaller ∆F value compared to non-polar solvent such as CCl4 which has larger
∆F value. DMSO and MeOH are organic solvents capable of solubilizing curcumin, smaller
∆F value in these solvents is expected as the free energy changes between bent and stretched
conformation is small, however, in water where curcumin has marginal solubility the small
∆F is due to the hydrophobicity property, as it will tend to avoid the contact with water and
tends to bent. To describe the influence of solvents on conformational changes of curcumin,
liquid dielectric constant is correlated with the ∆F value (Fig. 22b) which indicates that more
polar solvents with higher dielectric constant such as water have small change in free energy
as compared to less polar and /or non-polar such as CCl4 whose dielectric constant is lower.
These results further suggest that liquid dielectric constant influences conformation changes
of curcumin in a peculiar manner. Previously, using standard molecular dynamics simulation
with OPLS-UA force field and SPC/E water model for single curcumin molecule, Ilnytskyi et
al. (2016) reported the maxima conformation for ring-ring distance of ≈ 1 nm. The presented

















































Figure 22: (a) 1D free energy for end to end distances showing the minimum distances in different
solvents. (b) Shows the correlation (r2 =−0.59) between liquids dielectric constant (ε) and
free energy differences (∆F) on curcumin conformation changes.
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To understand the origin of these conformation changes in different solvents, dihedral angles
at the spacer region define as A1 and A2 (see Fig. 19) were biased. The measured dihedral
angles at A1 show the spacer connectivity between the two ring groups and provide information
regarding curcumin rotation. Figure 23a shows the 1D free energy profile for dihedral angles
of curcumin in different solvents. One can see a clear effect of solvent on the dihedral angle
distribution, two peculiar behaviours for curcumin in the solvent under study are observed, first
CCl4 is observed to have a φ rotation at ± 3 rad only, while in other solvents a rotation at
φ = 0 and ± 3 rad is observed, the effect of solvents is observed with different free energy
minima. The rotation at φ = ± 3 rad indicates the presence of trans-conformation and at φ =
0 indicates cis-conformation. In another way, in CCl4 only the trans-conformation is observed
while in other solvents both cis and trans-conformations are present. The cis-conformation
in water is more thermodynamic stable followed by MeOH, DMSO and least in DCM. It is
observed that solvent polarity play an important role in conformation changes and stability.
The cis-conformation is more stable in polar solvent and the stability decreases as the polarity





















































Figure 23: (a) 1D free energy on dihedral angle distributions. (b) The correlation (r2 =−0.95) between
relative solvent polarity and free energy for cis-conformation. CCl4 is removed for clarity of
the plot as it has larger free energy of 149 kJ/mol.
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4.2.4 Hydrogen bonds
Solute-solvent interaction involving donor or acceptor group results into formation of hydro-
gen bond and can portray kinetic information of the solute molecule. In order to understand the
effects of solvents on the hydrogen bond formed by curcumin and vicinal solvents, hydrogen
bond was computed by biasing the donor and acceptor groups in solvents and curcumin. Oxy-
gen groups in water and MeOH both can act as donor or acceptor while that in DMSO only acts
as donor. The contribution of acceptor or donor groups to hydrogen bonding in polar solvent is
nearly the same. As an example, in water the number of hydrogen bonds formed when water
acts as an acceptor or donor with the oxygen or hydrogen of curcumin molecules is almost the
same (Fig. 24b). However, the total number of hydrogen bonds formed (Fig. 24c) is different
in each solvent, with water having larger number of hydrogen bonds and least in DMSO.
(a) (b)
(c)
Figure 24: Hydrogen bonds formed between curcumin and water calculated using donor/acceptor
groups. (a) water is donor (b) water is acceptor. (c) total number of hydrogen bonds formed
in water, MeOH and DMSO.
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It is observed that solvent polarity plays an important role on hydrogen bond formation, as the
polarity decreases the number of hydrogen bonds also decreases in the order of water > MeOH
> DMSO. The number of acceptor groups play an important role on the formation of hydrogen
bonds. Water and MeOH are observed to have higher number of hydrogen bonds due to the
presence of an acceptor and donor groups, however, in DMSO this is not the case as the oxygen
in DMSO only acts as a donor group and can only form a hydrogen bond with acceptor groups
of curcumin molecule. The three solvents portray different hydrogen bonding properties due to
the difference in their polarity and presence of acceptor and donor groups.
4.3 Solvent effects on host-guest kinetics and residence time
Many complex biomolecules processes such as protein folding, aggregation, drug (un)binding
kinetics amongst others, usually take places in aqueous solutions and solvents play an impor-
tant role in aiding such processes (Jong et al., 2017). The effect of solvent in aiding such
processes usually occurs in a non-trivial manner. As an example, supramolecular drug inter-
actions usually take place in solvents which in-turn affect their interaction and eventually their
kinetics and residence time. Understanding such processes at molecular level provides a better
way in establishing the related solvent effects for such processes. The motivation of this thesis
was further to investigate the related solvents effect on drug kinetics and residence time at an
atomistic level based on chitosan nanoparticle and toussantine-A.
Toussantine-A (TouA) shown in Fig. 25 is a natural product with promising biological activities
including antitubercular and anticancer (Nyandoro et al., 2015). TouA was first isolated and
reported by Nyandoro et al. (2015), despite its promising biological activities, the molecule
showed chemical instability in various solvents during isolation. One of the proposed ways to
address the challenges of chemical instability is the use of supramolecular host-guest interac-
tion (Shan et al., 2014). In this approach, a drug is loaded into a host which is a nanoparticle
and transported or released to the specific site of action. Thus, polymers such as chitosan due to
their good biocompatibility, chemical stability, low cost, improved solubility and low toxicity
(Shan et al., 2014) have shown great potential in drug delivery systems. In this thesis, due
to the relevance that, drug formulation, synthesis and encapsulation, usually take place in sol-
vents (Carr et al., 2018), the solvent effects on the kinetics and residence time on the unbinding
process using TouA and chitosan nanoparticle as a model system are studied.
4.3.1 Structural changes of chitosan nanoparticles in DMSO and water
This subsection of the thesis begins by exploring the structural changes of chitosan nanopar-
ticle brought by the solvents. The solvents used viz. DMSO and water are polar aprotic and
polar protic, respectively, and have clinical relevance (Slabber et al., 2016). Their chemical





























(a) TouA 2D (b) TouA 3D
(c)
Figure 25: The chemical structures (a) 2D and (b) 3D representation of TouA, atoms are labeled by
color, oxygen is red, nitrogen is blue, hydrogen is while and carbon in light blue. (c) 2D
representation of DMSO and Water.
two solvents is investigated by measuring the solvent accessible surface area (SASA) which
provides information on the influence of solvent on structural changes. SASA provides infor-
mation on the segregation and aggregation of polymers and protein as well as describing the
number of unfavourable hydrophobic contacts between the protein and or polymers in solvents.
SASA values are measured from MD simulation of 100 ns and their results are presented in Fig.
26. The SASA value for DMSO is higher when compared to that in water which suggests the
formation of segregated structures, while lower value suggests the presence of aggregated struc-
ture in water. The aggregation of chitosan nanoparticle in water is explained by the presence of
hydrophobic groups which tend to aggregate when are in contact with water (Rampino et al.,
2013; Philippova et al., 2001; Wang et al., 2013; Franca et al., 2011). The size distribution
of chitosan nanoparticle in the two solvents is further described by calculating the free energy
of the SASA values as F = −kBT ln(P), where P is the probability and kB is the Boltzmann
constant and T is temperature. As shown in Fig. 26 the size of chitosan nanoparticle in DMSO
is 24.2 Å larger than in water which is 16.5 Å. The SASA results in the two solvents show
that chitosan nanoparticle has a larger size in DMSO than in water which may facilitate more
DMSO to enter into the nanoparticle and weaken the interaction hence TouA in DMSO could
be released more easily. To further ascertain this the number of solvent near TouA bound to chi-
tosan was measured using a distance cutoff of 3.5 Å. It was observed that few water molecules
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were present inside the chitosan which stabilize the interaction by formation of hydrogen bond
(Fig. 27), however, for DMSO system it was observed that more DMSO molecules enter into
the nanoparticle and destabilize the interaction as DMSO lacks an acidic hydrogen.
(a) (b)
(c) (d)
Figure 26: (a) and (c) are time dependent SASA values for chitosan nanoparticle in water and DMSO
solvents, respectively. (b) and (d) free energy as the function of SASA in water and DMSO,
respectively.
(a) (b)
Figure 27: Representative snapshots showing the number of solvents in the first hydration shell for TouA
bound to chitosan in (a) DMSO and in (b) water, chitosan is not shown for clarity.
58
4.3.2 Unbaised 1D free energy surfaces
The central idea of this subsection of the thesis is to understand the underlying effects of two
solvents namely DMSO and water on the unbinding residence time and kinetics of TouA from
chitosan nanoparticle. Free energies calculated from classical MD simulation and metadynam-
ics are used to provide insight on the unbinding rates, furthermore, thermodynamic integration
provides the related binding affinity. Before embarking to describe the residence time and ki-
netics on TouA unbinding, the thesis start by discussing the free energy surfaces obtained from
both unbiased and biased simulations. Although classical MD simulation has limitations related
to sampling problem, it provides the underlying picture of how the system behaves. In order to
capture the unbinding behaviour in the two solvents, first the time dependent for TouA-chitosan
minimum distance (dmin) over the simulation time of 140 ns in Fig. 28 are presented. The time
dependent provides some information on the unbinding process, one can see that in DMSO a
distance at 1.1-1.2 nm is mostly populated than in water where the distance at 0.35 nm most
populates. In order to quantify the effect of solvents on the unbinding process the free energy
(F) was calculated using the relation F = −kBT ln(P), where kB is the Boltzmann constant, T
is temperature and P is the probability. The free energy profiles presented in Fig. 28 suggest
a clear solvents effect on TouA-chitosan interaction. The free energies in DMSO and water
show a clear distinct free energy minima. The free energy for the unbinding state in DMSO
indicates the presence of two minima at 0.35 and 1.19 nm corresponding to bound and unbound
state, respectively. A more deeper minimum is observed for the unbound state as compared to
the bound state which suggests that the complex in DMSO solvent exists more in an unbound
state. However, in water a different behavior is observed, a deep free energy minimum was
observed at 0.35 nm corresponding to the bound state. The free energy for unbound state was
observed at a distance of 0.6 nm. The observed energy barrier for bound and unbound state in
water is 2-fold higher than that in DMSO, this further explains the reason why there is large
free energy in the unbound state in DMSO when compared to water. The differences in free
energy in the two solvents is further explained by weak intermolecular interaction in DMSO
than in water. The unbiased MD simulation provides an important feature on the system be-
haviour and suggests that the interaction in DMSO is poor which mostly favours the formation
of a larger product as evidenced by the small energy barrier which disfavour the reaction going
back to the reactants. Unlikely for water, the formation of the product is less favoured due to
large energy barrier. In order to provide more information, the next subsection presents and
discusses enhanced sampling results obtained using WT-MetaD which provide more insights
on the unbinding residence time and kinetics of TouA in chitosan nanoparticle.
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Figure 28: a-b, Time dependent for minimum distance between chitosan and TouA obtained from un-
biased MD simulation during the 140 ns. Free energy profiles as the function of minimum
distance between chitosan and TouA obtained from unbiased MD simulation, (c) in DMSO
and (d) in water. TS is the transition state or barrier
4.3.3 Baised 1D free energy surfaces
Because of the limitations of classical MD simulation in sampling rarely events and time con-
straints, solvent effects on drug unbinding kinetics and residence time are further investigated
by WT-MetaD in water and DMSO. To describe the effects of solvents on the unbinding pro-
cess, the following collective variables (CVs) are used: minimum distance (dmin) between spe-
cific groups of TouA defined in Fig. 25(a) and chitosan as CV5, coordination number between
chitosan and TouA as CV6 and torsional angles as CV7. In order to describe the effects of
solvents on the conformational changes of TouA bound to chitosan nanoparticle, the following
CVs are used: keto-enol distance, end to end distance and torsional angles. The time-dependent
of CV5 in the two solvents is presented in Fig. 29 which suggests system diffusivity with time
implying convergence of the system. Then, the free energy surfaces to describe the unbinding
process are calculated and discussed in the subsequent sections, first, the discussion begins by
describing the 1D-free energy of the unbinding process.
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In Figure 30 the 1D free energy surface along the minimum distance obtained for water and
DMSO systems are presented. The presented comparison helps to build the underlying intuition
on the effects of the solvent on drug unbinding kinetics and residence time. Visual inspection
on the 1D free energy indicates the two systems (water and DMSO) are different, suggesting
that solvents affect the kinetics and residence time during the unbinding process in a different
way. First, all systems show a similar binding behaviour characterized by a minimum distance
at 0.3 nm which corresponds to electrostatic interaction between the chitosan and TouA groups.
The effect of solvents is manifested by different free energies for the unbinding process as pre-
sented in Table 5 and Fig. 30, the free energy difference between the bound state and transition
state (TS) in water is 6-folds higher to that in DMSO system. The smaller barrier of 5 kJ/mol in
DMSO clearly shows that TouA would quickly be released, while in water it requires an amount
of 34 kJ/mol to cross the barrier and hence slowly released. This is mostly advantageous for
controlled drug delivery as it will take long time for the drug to be completely released. Based
on the energy barrier one can see that there is a fast rate for the unbinding of TouA in DMSO
than in water. Such differences could be brought by the difference in the electronegativity,
solvent dielectric constant and polarity of the solvents. Water being a more polar solvent with
higher dielectric constant results to formation of aggregated chitosan-TouA complex structure
with strong intermolecular interaction while DMSO a polar aprotic solvent with lower dielec-
tric constant tends to weaken the intermolecular hydrogen bonds formed between chitosan and
TouA and hence resulting to a fast unbinding rate. The presented thermodynamic data for both
water and DMSO systems integrate out the coordination number as the coordinate that would
characterize the binding and unbinding kinetics process. Thus, the next subsection presents and
discusses the 2D free energy surface obtained by biasing coordination number and minimum
distance (dmin).
Table 5: Free energy differences (∆F) between bound and TS (kJ/mol) as a function of minimum dis-
tance (dmin) for TouA binding in different solvents. ε is solvent dielectric constant and µ dipole
moment (D). The values for dipole moment and dielectric (ε) constant are taken from Reichardt
C., (2003).
Solvent µ(D) ε ∆F
Water 1.86 80.1 34



































Figure 29: Time dependent of TouA unbinding process from chitosan nanoparticle in (a) DMSO and (b)
Water.
4.3.4 2D free energy
The discussion begins by illustrating the 2D free energy surface obtained by biasing the min-
imum distance and coordination number as collective variables for both systems as shown in
Appendix 1. The free energy surface for DMSO system reveals more information on the bind-
ing and unbinding kinetics characterized by different structural feature with four minima along
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Figure 30: 1D free energy for the unbinding of TouA in water (black) and DMSO (red) as a function of
CV minimum distance (dmin). The vertical dash line represents an artifact caused by the wall
imposed during the simulation. TS is the transition state or barrier
the minimum distance and coordination number in different regions: As it has been observed
before, the bound structure corresponds to a minimum distance of 0.3 nm with a coordination
number of ≈ 3. The unbound state corresponds to a lower coordination number of less than
1. One can see that the bound and unbound minima are separated by other minima located at
dmin ≈ 0.4 and 0.55 nm with a coordination number of 0.5. Due to the small barrier as observed
in Fig. 30, TouA in DMSO could escape from the bound state to unbound state more easily and
hence released quickly from its carrier. This is also evidenced by the free energy for which has
a different of 1 kJ/mol. However, for the system containing water solvent, a different behaviour
is observed. One can see that the free energy for the bound state at dmin ≈ 0.3 and 0.4 nm is
large than the unbound state at dmin ≈ 1.2 nm, suggesting that, water influences the intermolec-
ular interaction of the two molecules by contributing the electrostatic interaction. Furthermore,
the bound state and unbound state are separated by the energy barrier of ≈ 31 kJ/mol, causing
TouA not to escape easily from its carrier.
The change of chemical environment is well appreciated to have a greater effect on the dy-
namics, thermodynamics and functions of biologically important molecules (Levy et al., 2001;
Papadakis & Deligkiozi, 2019). The function and thermodynamics of binding between host
and guest molecules can change when exposed to different solvents (Papadakis & Deligkiozi,
2019). This is evidenced by the free energy for the interaction of chitosan and TouA in DMSO
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and water solvents. In the former solvent, the interaction tends to be weak when compared to
the later solvent. This is attributed to the difference in polarity and electronegativity, as the
DMSO is less electronegative and polar aprotic. On the other hand, the strong binding state for
water is expected due to strong intermolecular interaction between water and chitosan/TouA.
This is because water molecule interacts with the polar group of chitosan/TouA to form hy-
drogen bonding. Likely, the destabilization of hydrogen bonding in DMSO system results in
weakening the interaction and hence TouA is released easier.
The choice of CVs is not a trivial process in metadynamics simulation, torsional angle (CV7)
and minimum distance (CV5) were further used to describe the kinetic and unbinding process
of TouA. Such CVs have been also used in protein-ligand unbinding kinetics experiment and
provided useful insights into ligand unbinding (Limongelli et al., 2013). In addition, the CVs
are used to show the conformation change and motion of ligand as it unbinds. Using these CVs
one can see that the system in water visits the bound state several times with a dmin < 0.6 nm and
torsional angle φ = ±3 rad. The corresponding free energy and associated structures to aid the
discussion are presented in Fig. 31. Two energy basins A and B are observed for bound state,
however, basin B is the preparation state for TouA to unbind from chitosan. At this basin TouA
orients in a such way it starts to be expelled out from chitosan. Another important observation
from basin B is that, at this state chitosan also undergoes conformation adaptability which
favour TouA to be released.It is worth to note that the conformational adaptability of chitosan
at basin B is different to that in A. In the unbound state basin C, TouA has no contacts with
its carrier and has several orientations and chitosan retain its conformation similar to that in
basin B. In DMSO, a completely reverse process where the unbound basin C is observed with
large free energy than the bound basin A. An intermediate state for unbinding is observed at
basin B before TouA is completely unbound and full solvated. In a closer observation, solvent
effects on the orientation of TouA is well manifested in the bound and unbound basins in the
two solvents. In water the orientation with large free energy at φ = π/2 and π rad, while in
DMSO both bound and unbound basins shows the rotation at φ = π rad was observed. Visual
inspection to the snapshots show that the functionalized TPP groups play an important role in





Figure 31: (a) Binding and unbinding processes of TouA in water. Atoms are shown by their colour:
Hydrogen is white, Oxygen is red, Nitrogen is blue and Carbon is light blue. (b) the binding
conformation corresponds to A while unbinding conformation are labled B and C in DMSO.
4.3.5 Drug kinetics and residence time (τAB)
As described earlier, drug kinetics and residence time play an important role in drug design.
The residence time defined as the reciprocal of the dissociation rate constant (τ = 1/koff) is
known to depend on conformations stabilization. In this work the time taken by TouA from the
bound to unbound state is quantified,
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As presented in Fig. 37, the free energy for the bound and unbound states is related to the ac-
tivation barrier for the host-guest dissociation, which describes the rate of the reaction. Higher
activation barrier results to slow reaction rates. The time exchange from a bound to unbound
state (dissociation) is an important parameter to describe the rate of the reaction. In this work,
τex is the time exchange for TouA from state A (bound) to B (unbound) and has an average






































Figure 32: Time exchange τex from bound to unbound state in (a) DMSO and (b) water.
Table 6 shows the results for τAB in different solvents. One can see that there is solvent effect
on the kinetics and residence time of TouA to unbound from chitosan. In water, TouA shows
a slow rate of koff = 0.045/µs compared to DMSO where the koff is fast 1000 times. The
koff values suggest that TouA in presence of DMSO is expelled out from chitosan faster and
has weak interaction than in water. As previously reported (Levy et al., 2001; Papadakis &
Deligkiozi, 2019) that solvent affects the kinetics and supramolecular host-guest interaction, the
current results suggest that the interaction of chitosan and TouA is highly solvent dependent.
To attain an optimal release of TouA from chitosan, this study suggests that the formulation
should be done in water and not DMSO. Until the time of writing this thesis, there isn’t any
experimental work which reports the experimental formulation of chitosan-TouA in DMSO.
However, the formulation of chitosan-TouA in water has been previously reported (Rwegasila
et al., 2018). The computational results on drug kinetics and residence time in water reported
in this thesis can be compared to the experimental work, where the release kinetics of TouA
was sustained for 72 hrs similar to the obtained slow rate, suggesting a slow release of TouA
in water. Similarly, the experimental encapsulation efficiency and loading capacity are also
compared to free energy landscape where in water a large free energy in a bound state was
observed which supports strong supramolecular interaction. The reported findings are useful
and provide a piece of baseline information on how one can decide to choose a solvent for
supramolecular interaction.
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Table 6: Residence time (τAB) and kinetics rate (koff) for unbinding process of TouA in two solvents.
System τAB(µs) koff /µs
water 22 0.045
DMSO 0.001 1000
4.3.6 Conformation of TouA bound to chitosan in solvents
Furthermore, the kinetic and residence time of TouA to its stability in the two solvents are
linked. In order investigate the stability the following CVs were biased: keto-enol distance
formed by atoms 11 and enolic group 12, end to end distance formed by atoms 7 and 21 and
spacer dihedral angles formed by atoms 8, 14, 16, 17 to determine internal changes in TouA
molecule. Figure 33 shows the 1D free energy as the function of keto-enol distance. One
can see that, the keto-enol distance shows a minimum at dmin ≈ 0.35 and 0.55 nm suggesting
that TouA exists with a conformation of enolic hydrogen pointing towards the keto oxygen
and away from the keto oxygen as shown in Fig. 34c. The distance at 0.35 nm suggests an
intramolecular interaction of TouA molecule while the distance at 0.55 nm suggests an inter-
molecular interaction with chitosan or solvent as shown in an insert in Fig. 33. Table 7 further
shows the free energy difference (∆F) for keto-enol distances in the two solvents. In both sol-
vents one can observe a conformation at a distance of 0.55 nm to be dominated, suggesting that,
although TouA may form intramolecular hydrogen bonding, it exists in a stable conformation
with the enolic hydrogen pointing away from the keto oxygen. However, comparing the two
free energies in water and DMSO one can see large free energy in water. This behaviour is ex-
pected as a result of higher electronegativity tendency of water molecule which tends to form
intermolecular interaction with the enolic hydrogen of TouA causing a C-O bond rotation (see
an insert in Fig. 33). To capture more information on the TouA kinetics, Fig. 34 shows the 2D
free energy as a function of CV3 and CV4. Different behaviours of TouA in the two solvents
is portrayed. In DMSO TouA shows two minima for the keto-enol distance while the end to
end distance shows a stable minimum at ≈ 1.2 nm suggesting that TouA in DMSO exists more
in stretched conformation. However, this is not the case in water where two distinct minima
corresponding for bent and stretched conformation are observed. For further discuss, as an
example, the associated structures at each state in Fig. 34c are presented. Both 1D and 2D
free energies in two solvents portray a different behaviour and stability, where in water TouA
is 2-folds thermodynamic stable than in DMSO. The measured dihedral angles and end to end
distances are presented in Fig. 35, the dihedral angles φ further show a rotational at φ = ±3
rad with a more stretched conformation in DMSO and both bent and stretched conformation






















Figure 33: 1D free energy on solvent effects on TouA keto-enol distance when bound to chitosan. An
insert shows the intermolecular interaction between TouA and water.













































































Figure 34: a-b, 2D free energy of TouA conformation when bound to chitosan (a) in DMSO and (b) in
water. (c) is the conformation of TouA bound to chitosan in water taken at the following
coordinates A (0.319,1.19), B (0.51,0.95) and C (0.509,0.386).
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Figure 35: Orientations of TouA bound to chitosan in two solvents. (a) in DMSO and (b) in water.
4.3.7 Thermodynamic stability of chitosan-TouA complex
Previous subsections have explored the solvent related effects on kinetics and residence time
of chitosan-TouA complex in DMSO and water. This subsection describes the solvent effects
on the thermodynamic stability of the complex in solvents. Previously, it has been shown that,
changes in solvent polarity has a drastic effects on the thermodynamics stability of the complex
(Papadakis & Deligkiozi, 2019). The thermodynamic stability of chitosan-TouA complex in
two solvents is further investigated by means of TI free energy. Although it is computation-
ally expensive, TI is an effective method for calculating the binding free energy of host-guest
molecules in solvents. The calculated TI binding free energy presented in Table 8 further shows
the related solvent effects on thermodynamics stability of the complex. The thermodynamics
stability for chitosan-TouA are different in these two solvents where in water more stable com-
plex was observed than in DMSO. This is because highly polar solvents such as water have
major effects on supramolecular host-guest complexes (Papadakis & Deligkiozi, 2019). These
result suggests that, although water results to thermodynamics stable complex, DMSO has a
reverse effect. Unfortunately, the favourable interaction in DMSO was not obtained as the free
energy was > 30 kcal/mol. Reverse effect of solvents on supramolecular complexes has also
been previously observed for different solvents (Kang & Rebek Jr, 1996). In this thesis, both
metadynamics and TI deciphered information on the interaction of chitosan-TouA in DMSO
to be more weaker and unfavourable when compared to water where there is favourable and
strong interaction.
Generally, the preceding discussion has demonstrated the effects of solvents on biomolecular
host-guest kinetics and residence time. Two solvents DMSO and water were used to study the
influence of solvents. It was observed that more polar protic solvent results to more stabilization
of host-guest interactions and polar aprotic solvents tend to have reverse effects on the binding
process favouring high unbinding rates. This influence can also be attributed to the nature of
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the encapsulated drug molecules. A similar approach can be extended to investigate host-guest
interaction for different nanoparticle and drugs.
Table 8: Thermodynamic integration (TI) binding free energy for chitosan-TouA complex in DMSO and
water.
System ∆Gbinding kcal/mol
DMSO poor bound (>30)





This thesis has investigated the role of solvents in conformational fluctuations and drug in-
teraction with an implication for drug design and discovery. The thesis has explored various
docking protocols used in drug design and discovery, the following conclusions are drawn from
the study:
(i) There is a sensitivity of results to different docking protocols. The use of ensemble struc-
tures with and without water reduced the binding energies compared to crystal structures.
(ii) Holo ensembles with ligands that bound strongly increase the binding energy close to
crystal structures. The use of ensemble structures holo or apo can improve the binding
energy, but this is not always the case. The docking protocols reported here pave the way
on drug design and suggest an integration of such protocols for various protein-ligand
complex.
(iii) Using metadynamics, an enhanced sampling approach, the thesis also investigated the
effects of different solvents on the stability, conformation and orientation of natural prod-
ucts using curcumin as a model molecule in polar protic, polar aprotic and non-polar
solvents. The conformation and stability of curcumin is solvent dependent. It is further
observed that stability and conformation of curcumin depend on solvent polarity.
(iv) Solvents play a major role in determining molecules conformation, stability and biolog-
ical functions. To further ascertain this thesis investigated solvent effects on host-guest
kinetics and residence time using chitosan-TouA in DMSO and water as model systems.
High unbinding kinetics rate (koff) in DMSO and slow unbinding kinetics (koff) in water
were observed. TouA was observed to be released more quickly in DMSO than in water.
(v) The approaches used in this study viz: different docking protocols, role of solvents on
drug interactions with protein and nanoparticles (macromolecules) are recommended for
applications in various drug design targeting several indications.
5.2 Recommendations
The following recommendations are drawn from the study:
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(i) The small molecules reported in this thesis as potential inhibitors for Hsp90 posses known
pharmacological profiles and are used for treatment of other indications. These molecules
are highly recommended for further pre-clinical and clinical studies as cancer chemother-
apeutic agents targeting Hsp90.
(ii) The exploration of natural product crystals heterogeneity interaction with solvents such as
water is highly recommended for a deeper understanding of the behaviour of water near
the natural products/drug crystal surface. This will further provide more understanding
of the issues of solubility and stability of molecules in different solvents. Studies leading
to the investigation of heterogeneity at curcumin crystal water interface is highly recom-
mended for better understanding of the origin of poorly water solubility of curcumin.
(iii) Investigation of the crystal growth and polymorphism changes of the investigated small
molecules is highly recommended to establish their related stability.
73
Abbasi, M., Sadeghi-Aliabadi, H., & Amanlou, M. (2018). 3d-qsar, molecular docking, and
molecular dynamic simulations for prediction of new hsp90 inhibitors based on isoxazole
scaffold. Journal of Biomolecular Structure and Dynamics, 36(6), 1463–1478.
Abraham, M., van der Spoel, D., Lindahl, E., & Hess, B. (2015). The gromacs development
team gromacs user manual version 5.1. 2; 2016. SoftwareX, 1, 19.
Aldeghi, M., Bluck, J. P., & Biggin, P. C. (2018). Absolute alchemical free energy calculations
for ligand binding: A beginners guide. In Computational Drug Discovery and Design.
Springer.
Aldeghi, M., Heifetz, A., Bodkin, M. J., Knapp, S., & Biggin, P. C. (2016). Accurate calculation
of the absolute free energy of binding for drug molecules. Chemical Science, 7(1), 207–
218.
Amaro, R. E., Baron, R., & McCammon, J. A. (2008a). An improved relaxed complex scheme
for receptor flexibility in computer-aided drug design. Journal of Computer-Aided Molec-
ular Design, 22(9), 693–705.
Amaro, R. E., Schnaufer, A., Interthal, H., Hol, W., Stuart, K. D., & McCammon, J. A. (2008b).
Discovery of drug-like inhibitors of an essential rna-editing ligase in trypanosoma brucei.
Proceedings of the National Academy of Sciences, 105(45), 17278–17283.
Austin, C., Pettit, S. N., Magnolo, S. K., Sanvoisin, J., Chen, W., Wood, S. P., Freeman, L. D.,
Pengelly, R. J., & Hughes, D. E. (2012). Fragment screening using capillary electrophore-
sis (cefrag) for hit identification of heat shock protein 90 atpase inhibitors. Journal of
Biomolecular Screening, 17(7), 868–876.
Barakat, K., Mane, J., Friesen, D., & Tuszynski, J. (2010). Ensemble-based virtual screen-
ing reveals dual-inhibitors for the p53–mdm2/mdmx interactions. Journal of Molecular
Graphics and Modelling, 28(6), 555–568.
Barakat, K., & Tuszynski, J. (2011). Relaxed complex scheme suggests novel inhibitors for
the lyase activity of dna polymerase beta. Journal of Molecular Graphics and Modelling,
29(5), 702–716.
Barducci, A., Bussi, G., & Parrinello, M. (2008). Well-tempered metadynamics: a smoothly
converging and tunable free-energy method. Physical Review Letters, 100(2), 020603.
74
REFERENCES
Barker, J. J., Barker, O., Courtney, S. M., Gardiner, M., Hesterkamp, T., Ichihara, O., Mather,
O., Montalbetti, C. A., Müller, A., & Varasi, M. (2010). Discovery of a novel hsp90
inhibitor by fragment linking. Chemmedchem, 5(10), 1697–1700.
Baum, B., Mohamed, M., Zayed, M., Gerlach, C., Heine, A., Hangauer, D., & Klebe, G.
(2009). More than a simple lipophilic contact: a detailed thermodynamic analysis of
nonbasic residues in the s1 pocket of thrombin. Journal of Molecular Biology, 390(1),
56–69.
Baum, B., Muley, L., Smolinski, M., Heine, A., Hangauer, D., & Klebe, G. (2010). Non-
additivity of functional group contributions in protein–ligand binding: a comprehensive
study by crystallography and isothermal titration calorimetry. Journal of Molecular Biol-
ogy, 397(4), 1042–1054.
Berendsen, H. J., Postma, J. V., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984).
Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics,
81(8), 3684–3690.
Bhat, R., Tummalapalli, S. R., & Rotella, D. P. (2014). Progress in the discovery and develop-
ment of heat shock protein 90 (hsp90) inhibitors: Miniperspective. Journal of Medicinal
Chemistry, 57(21), 8718–8728.
Bissantz, C., Kuhn, B., & Stahl, M. (2010). A medicinal chemists guide to molecular interac-
tions. Journal of Medicinal Chemistry, 53(14), 5061–5084.
Bonomi, M., Branduardi, D., Bussi, G., Camilloni, C., Provasi, D., Raiteri, P., Donadio, D.,
Marinelli, F., Pietrucci, F., & Broglia, R. A. (2009). Plumed: A portable plugin for
free-energy calculations with molecular dynamics. Computer Physics Communications,
180(10), 1961–1972.
Brice, A. R., & Dominy, B. N. (2011). Analyzing the robustness of the mm/pbsa free energy
calculation method: application to dna conformational transitions. Journal of Computa-
tional Chemistry, 32(7), 1431–1440.
Brooijmans, N. (2009). Docking methods, ligand design and validating data sets in the struc-
tural genomics era. John Wiley & Sons Inc.: New York, NY, USA.
Bussi, G., Donadio, D., & Parrinello, M. (2007). Canonical sampling through velocity rescal-
ing. The Journal of Chemical Physics, 126(1), 014101.
75
Carr, A. C., Piunova, V. A., Maarof, H., Rice, J. E., & Swope, W. C. (2018). Influence of
solvent on the drug-loading process of amphiphilic nanogel star polymers. The Journal of
Physical Chemistry B, 122(21), 5356–5367.
Cavasotto, C. N., Orry, W., & Andrew, J. (2007). Ligand docking and structure-based virtual
screening in drug discovery. Current Topics in Medicinal Chemistry, 7(10), 1006–1014.
Cavenagh, J., Oakervee, H., Baetiong-Caguioa, P., Davies, F., Gharibo, M., Rabin, N., Kurman,
M., Novak, B., Shiraishi, N., & Nakashima, D. (2017). A phase i/ii study of kw-2478,
an hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory
multiple myeloma. British Journal of Cancer, 117(9), 1295.
Chan, A. H., Wereszczynski, J., Amer, B. R., Yi, S. W., Jung, M. E., McCammon, J. A., &
Clubb, R. T. (2013). Discovery of s taphylococcus aureus sortase a inhibitors using virtual
screening and the relaxed complex scheme. Chemical Biology & Drug Design, 82(4),
418–428.
Chatterjee, S., & Burns, T. (2017). Targeting heat shock proteins in cancer: a promising thera-
peutic approach. International Journal of Molecular Sciences, 18(9), 1978.
Cheatham, T. I., Miller, J., Fox, T., Darden, T., & Kollman, P. (1995). Molecular dynamics
simulations on solvated biomolecular systems: the particle mesh ewald method leads to
stable trajectories of dna, rna, and proteins. Journal of the American Chemical Society,
117(14), 4193–4194.
Chen, F., Liu, H., Sun, H., Pan, P., Li, Y., Li, D., & Hou, T. (2016). Assessing the performance
of the mm/pbsa and mm/gbsa methods. 6. capability to predict protein–protein binding
free energies and re-rank binding poses generated by protein–protein docking. Physical
Chemistry Chemical Physics, 18(32), 22129–22139.
Cheng, L. S., Amaro, R. E., Xu, D., Li, W. W., Arzberger, P. W., & McCammon, J. A. (2008).
Ensemble-based virtual screening reveals potential novel antiviral compounds for avian
influenza neuraminidase. Journal of Medicinal Chemistry, 51(13), 3878–3894.
Chiosis, G. (2006). Discovery and development of purine-scaffold hsp90 inhibitors. Current
Topics in Medicinal Chemistry, 6(11), 1183–1191.
Comeau, S. R., Gatchell, D. W., Vajda, S., & Camacho, C. J. (2004). Cluspro: a fully automated
algorithm for protein–protein docking. Nucleic Acids Research, 32(2), 96–99.
76
Cui, D., Zhang, B. W., Matubayasi, N., & Levy, R. M. (2018). The role of interfacial water
in protein–ligand binding: Insights from the indirect solvent mediated potential of mean
force. Journal of Chemical Theory and Computation, 14(2), 512–526.
da Silva, G. C., Cardozo, T. M., Amarante, G. W., Abreu, C. R., & Horta, B. A. (2018). Solvent
effects on the decarboxylation of trichloroacetic acid: insights from ab initio molecular
dynamics simulations. Physical Chemistry Chemical Physics, 20(34), 21988–21998.
Darden, T., York, D., & Pedersen, L. (1993). Particle mesh ewald: An n log (n) method for
ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092.
David, L., Nielsen, P. A., Hedstrom, M., & Norden, B. (2005). Scope and limitation of ligand
docking: Methods, scoring functions and protein targets. Current Computer-Aided Drug
Design, 1(3), 275–306.
de Graaf, C., Oostenbrink, C., Keizers, P. H., van der Wijst, T., Jongejan, A., & Vermeulen,
N. P. (2006). Catalytic site prediction and virtual screening of cytochrome p450 2d6 sub-
strates by consideration of water and rescoring in automated docking. Journal of Medici-
nal Chemistry, 49(8), 2417–2430.
De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. (2016). Role of molecular dynamics and
related methods in drug discovery. Journal of Medicinal Chemistry, 59(9), 4035–4061.
Dias, R., de Azevedo, J., & Walter, F. (2008). Molecular docking algorithms. Current Drug
Targets, 9(12), 1040–1047.
Dominguez, C., Boelens, R., & Bonvin, A. M. (2003). Haddock: a protein- protein dock-
ing approach based on biochemical or biophysical information. Journal of the American
Chemical Society, 125(7), 1731–1737.
Durrant, J. D., & McCammon, J. A. (2011). Molecular dynamics simulations and drug discov-
ery. BMC Biology, 9(1), 71.
Eachkoti, R., Reddy, M. R., Lieu, Y. K., Cosenza, S. C., & Reddy, E. P. (2014). Identification
and characterisation of a novel heat shock protein 90 inhibitor ono4140. European Journal
of Cancer, 50(11), 1982–1992.
Ernst, J. T., Neubert, T., Liu, M., Sperry, S., Zuccola, H., Turnbull, A., Fleck, B., Kargo,
W., Woody, L., & Chiang, P. (2014). Identification of novel hsp90α/β isoform selective
inhibitors using structure-based drug design. demonstration of potential utility in treating
cns disorders such as huntingtons disease. Journal of Medicinal Chemistry, 57(8), 3382–
3400.
77
Franca, E. F., Freitas, L. C., & Lins, R. D. (2011). Chitosan molecular structure as a function
of n-acetylation. Biopolymers, 95(7), 448–460.
Fu, I. W., Markegard, C. B., & Nguyen, H. D. (2014). Solvent effects on kinetic mechanisms
of self-assembly by peptide amphiphiles via molecular dynamics simulations. Langmuir,
31(1), 315–324.
Ge, J., Normant, E., Porter, J. R., Ali, J. A., Dembski, M. S., Gao, Y., Georges, A. T., Grenier,
L., Pak, R. H., & Patterson, J. (2006). Design, synthesis, and biological evaluation of hy-
droquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble
inhibitors of hsp90. Journal of Medicinal Chemistry, 49(15), 4606–4615.
Genheden, S., & Ryde, U. (2015). The mm/pbsa and mm/gbsa methods to estimate ligand-
binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461.
Gereben, O., & Pusztai, L. (2011). On the accurate calculation of the dielectric constant from
molecular dynamics simulations: The case of spc/e and swm4-dp water. Chemical Physics
Letters, 507(1-3), 80–83.
Gewirth, D. T. (2016). Paralog specific hsp90 inhibitors–a brief history and a bright future.
Current Topics in Medicinal Chemistry, 16(25), 2779.
Grubmüller, H. (1995). Predicting slow structural transitions in macromolecular systems: Con-
formational flooding. Physical Review E, 52(3), 2893.
Gupta, S. D., Bommaka, M. K., Mazaira, G. I., Galigniana, M. D., Subrahmanyam, C. V. S.,
Gowrishankar, N. L., & Raghavendra, N. M. (2015). Molecular docking study, synthesis
and biological evaluation of mannich bases as hsp90 inhibitors. International Journal of
Biological Macromolecules, 80, 253–259.
Gupta, S. D., Snigdha, D., Mazaira, G. I., Galigniana, M. D., Subrahmanyam, C., Gowris-
hankar, N., & Raghavendra, N. (2014). Molecular docking study, synthesis and biological
evaluation of schiff bases as hsp90 inhibitors. Biomedicine & Pharmacotherapy, 68(3),
369–376.
Hani, U., & Shivakumar, H. (2014). Solubility enhancement and delivery systems of curcumin
a herbal medicine: A review. Current Drug Dselivery, 11(6), 792–804.
Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., & Hutchison, G. R.
(2012). Avogadro: an advanced semantic chemical editor, visualization, and analysis
platform. Journal of Cheminformatics, 4(1), 17.
78
Hazra, M. K., Roy, S., & Bagchi, B. (2014). Hydrophobic hydration driven self-assembly of
curcumin in water: Similarities to nucleation and growth under large metastability, and an
analysis of water dynamics at heterogeneous surfaces. The Journal of Chemical Physics,
141(18), 18C501.
Hernández-Rodrı́guez, M., Correa-Basurto, J., Gutiérrez, A., Vitorica, J., & Rosales-
Hernández, M. C. (2016). Asp32 and asp228 determine the selective inhibition of bace1 as
shown by docking and molecular dynamics simulations. European Journal of Medicinal
Chemistry, 124, 1142–1154.
Hertlein, E., Wagner, A. J., Jones, J., Lin, T. S., Maddocks, K. J., Towns, W. H., Goettl, V. M.,
Zhang, X., Jarjoura, D., & Raymond, C. A. (2010). 17-dmag targets the nuclear factor-κb
family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implica-
tions of hsp90 inhibition. Blood, 116(1), 45–53.
Hess, B., Bekker, H., Berendsen, H. J., & Fraaije, J. G. (1997). Lincs: a linear constraint solver
for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472.
Hevener, K. E., Zhao, W., Ball, D. M., Babaoglu, K., Qi, J., White, S. W., & Lee, R. E. (2009).
Validation of molecular docking programs for virtual screening against dihydropteroate
synthase. Journal of Chemical Information and Modeling, 49(2), 444–460.
Horn, H. W., Swope, W. C., Pitera, J. W., Madura, J. D., Dick, T. J., Hura, G. L., & Head-
Gordon, T. (2004). Development of an improved four-site water model for biomolecular
simulations: Tip4p-ew. The Journal of Chemical Physics, 120(20), 9665–9678.
Hou, T., Wang, J., Li, Y., & Wang, W. (2010). Assessing the performance of the mm/pbsa and
mm/gbsa methods. 1. the accuracy of binding free energy calculations based on molecular
dynamics simulations. Journal of Chemical Information and Modeling, 51(1), 69–82.
Huang, W., Blinov, N., Wishart, D. S., & Kovalenko, A. (2015). Role of water in ligand binding
to maltose-binding protein: insight from a new docking protocol based on the 3d-rism-kh
molecular theory of solvation. Journal of Chemical Information and Modeling, 55(2),
317–328.
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Figure 36: Time dependence for end to end distance in different solvents, (a) vacuum, (b) water, (c)
DMSO, (d) DCM, (e) MeOH and (f) CCl4.
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Chitosan-TouA supramolecular interaction.
(a) DMSO (b) Water
Figure 37: 2D free energy as a function of minimum distance and coordination number in two solvents.
In both solvents, minimum A and B corresponds to bound conformation while minimum D
corresponds the unbound conformations. In DMSO large free energy for unbound is observed
compared to the system in water.
Thermodynamics integration.




























Figure 38: Free energy change breakdown for chitosan-TouA complex in water
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Figure 39: Free energy for chitosan-TouA complex in water







































































































































































































Figure 41: MBAR convergence of free energy for the complex in water
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